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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1. Biological Engineering 
Since its origins dating from the end of the 19th century, chemical engineering (CE) has undergone 
profound and remarkable transformations (Chiarappa et al., 2017). Indeed, CE developed in 
Germany, Great Britain, and the USA, all of them already playing a prominent role in chemistry 
at the end of the 19th century (Peppas and Langer, 2004). For instance, Lewis M. Norton 
established, at the Department of Chemistry of MIT in Boston, a course in CE concerning the 
activities conducted in the German chemical industry, the actual leader in chemistry at that time. 
Frank T. Horpe, holding a B.S. degree from MIT and a doctorate from the University of Heidelberg 
in 1893 and Norton’s successor as professor of the aforementioned course, published, in 1898, the 
first book on CE entitled “Outlines of Industrial Chemistry”. While Norton and Thorpe may be 
considered the ancestors of CE, Arthur A. Noyes and afterward William H. Walker (1869-1934) 
were the first to describe the key features of chemical engineer’s curriculum (Peppas, 1989). 
Meanwhile, in Great Britain, Davis, by publishing a book entitled “Handbook of Chemical 
Engineering” in 1904, became the father of the concept of unit operation which implies the 
subdivision of chemical processes in different parts such as, for instance, distillation, extraction, 
filtration, and crystallization, each one governed by distinct principles. The foundation of the 
American Institute of Chemical Engineers (AIChE) in 1908 definitively gave birth to CE. 
Obviously, in these early stages of development of the new discipline, the debate over the 
background knowledge of a chemical engineer was very intense. Milton C. Whitaker, professor of 
CE at Columbia University and, in addition to his early membership, AIChE president in 1914, 
stated that chemistry, physics, and mathematics together with notions of mechanics, electricity, 
and economics should have constituted the basic knowledge of a chemical engineer. He also 
emphasized the fundamental difference between chemists and chemical engineers as the ability of 
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the latter to transfer laboratory findings to the industrial production. Around 1920 and until the 
beginning of World War II, further developments in the field of unit operations and the subsequent 
introduction of thermodynamics and chemical kinetics significantly contributed to the success of 
CE. Then, around 1950, the development of the new discipline (CE) underwent a rapid acceleration 
and a definitive separation from chemistry due to the merit of five American researchers: Neal R. 
Amundson and Rutherford Aris from the University of Minnesota, R. Byron Bird, Edwin N. 
Lightfoot, and Warren E. Stewart from the University of Wisconsin. They promoted the innovative 
idea of a common feature unifying the apparently different unit operations and the equations of 
conservation of mass, energy, and momentum. The practice of analyzing separately the various 
unit operations persisted, but differential volume and balance equations became the core of the 
new approach to solving chemical engineers’ problems. Approximately five years after the 
publication of “Transport Phenomena” (1960), the famous book written by Bird, Stewart, and 
Lightfoot, the concept of unit operation became obsolete and the new approach definitively 
affirmed in the research and education fields. 
In Italy and other industrially less developed countries, CE advancement followed the American 
one. In fact, the origins of Italian CE date from the end of World War II, when Italy experienced 
its economic recovery. However, a clear evidence of the existence of CE in Italy was provided 
only in the ’50s. Indeed, in those years, a major contribution to the growth of Italian chemical 
industry and CE was the nationalization of electricity production (sadly connected with the 
“announced” tragedy of Vajont in northern Italy (Paolini and Vacis, 1997)) and the consequent 
establishment of the National Board for Electricity (Enel). As a result, Edison, the main Italian 
private producer of electricity at that time, received full compensation from the Italian government 
for the expropriation of its power plants and invested that money in the sector of the chemical 
industry. Therefore, the necessity of rapidly acquiring the appropriate scientific and technical 
background knowledge without resorting to a slow research process required making a direct 
approach to consolidated German chemical companies such as BASF and Bayer. The exigencies 
of a close link between the investor and the German technical counterpart led, in 1958, to the 
foundation of the Italian Association of Chemical Engineering (AIDIC) and the Italian chemical 
industrial parks of Marghera, Mantua, and Priolo date from that period. Since then the 
development has been rapid, various, and rich in passionate discussions regarding the optimal 
organization at the national level (Astarita, 1980). 
CE attitude to traditionally distant cultural horizons such as medicine, biology, and pharmacy 
became evident only in the mid-seventies, even though the birth of Biological Engineering (BE) 
may be dated around the early sixties (Peppas and Langer, 2004). This evolution was due to 
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talented American researchers (Elmer L. Gaden, Arthur B. Metzner, R. Byron Bird, Edward W. 
Merrill) who realized that chemical engineers could usefully contribute to areas different from the 
traditional ones. Accordingly, they underlined the importance of an interdisciplinary approach 
which would have successively proved to be a winning strategy in modern research. Obviously, 
the realization of such a profound change was possible because major American organizations 
such as the National Science Foundation and the National Institutes of Health decided to invest in 
these innovative methodological approaches to medicine, biology, and pharmacy. As a result, 
between the early sixties and the late seventies, Merril (1959) investigated blood rheology, 
Leonard (1959) designed an artificial kidney, Colton (1966) focused on hemodialysis, Peppas 
worked on contact lenses (1976) and smart hydrogels (1979), while Langer (1979) explored the 
drug release from polymeric matrices. As so often happens, the first involvement of a chemical 
engineer in the biomedical field was completely fortuitous as a Boston physician requested 
Merrill’s help in solving a problem concerning the measurement of blood viscosity. Consequently, 
relevant information regarding the non-Newtonian properties of blood related to the strain rate, 
hematocrit, and to the presence of various proteins and white blood cells were gathered. Due to 
the development of mathematical models and computing power since the early eighties, CE could 
spread to areas of medicine hitherto unthinkable. In this regard, it is worth mentioning the study 
of the formation of atherosclerotic plaques based on mathematical models considering the mass 
transport in blood owing to diffusion, convection, carrier-mediated and vesicular transport 
mechanisms (Feig et al., 1982). 
A noticeable contribution of chemical engineers to biomedicine also concerned biomaterials such 
as hydrogels. Indeed, these materials, although available since 1935, became the subject of intense 
interest only after the pioneering work of Wichterle and Lim (Wichterle and Lim, 1960), the first 
to prepare polyhydroxyethylmethacrylate-based gels, the basic constituent of soft contact lenses 
since the ʼ70s. Moreover, applied thermodynamics and molecular theories made a major 
contribution to understanding and designing the properties of various biomaterials. Another topic 
covered by chemical engineers and very close to biomedicine consisted in designing living tissues. 
The guiding principle of tissue engineering states that the formation of tissues or parts of human 
organs requires an appropriate spatial arrangement of cells. This may be realized by seeding cells 
in suitable porous polymeric structures called scaffolds, i.e. a support or a matrix facilitating the 
migration, binding, and the transport of cells or bioactive molecules to replace, repair, and 
regenerate tissues (ASTM, 2007). For instance, it was possible to obtain human nervous tissues, 
cartilage, and hepatocytes (Folkman and Haudenschild, 1980; Bissell and Barcellos-Hoff, 1983; 
Vacanti et al., 1988). Similarly, chemical engineers encapsulated cells in polymeric structures in 
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order to obtain the so-called immunoisolation membranes, which are permeable to small molecules 
such as glucose or other nutrients but impermeable to large molecules such as immunoglobulins 
and the cells of the immune system. 
One of the fruits of this sparkling cultural context is the recent foundation of the Society for 
Biological Engineering (SBE) by AIChE, whose aim is to promote engineers and scientists to 
advance the integration between biology and engineering. Nevertheless, one of the most important 
contributions of CE to the biomedical field thus far has undoubtedly been drug delivery 
committing a large number of chemical engineers, among whom Peppas and Langer should be 
remembered. 
 
1.2. Quantitative System Pharmacology 
All the previous considerations perfectly match an emerging discipline named quantitative systems 
pharmacology (QSP), which dates from the beginning of the third millennium but has become 
known to a wider audience since 2010 (Sorger et al., 2011; Knight-Schrijver et al., 2016). Similarly 
to other disciplines, QSP has been evolving through independent innovative efforts rather than an 
overarching strategic plan (Musante et al., 2016). While different definitions may be found in 
literature (Sorger et al., 2011), QSP may be defined as the quantitative analysis of the dynamic 
interactions between drug(s) and a biological system aiming to understand the behavior of the 
entire system rather than that of its individual components (van der Graaf et al., 2011; Gadkar et 
al., 2016). Accordingly, the output of QSP is a knowledge base or a model with predictive 
capabilities to, for instance, enhance drug discovery, rationalize drug action, predict individual 
response to treatment, assess drug efficacy and safety, enable a rational design of clinical trials 
and an equally rational interpretation of their results (Knight-Schrijver et al., 2016; Androulakis, 
2016). Consequently, QSP also has a multidisciplinary approach, mathematics, engineering, 
physics, biology, and pharmacy being its roots. Indeed, this is the only way to provide creative and 
innovative solutions to the increasingly complex problems posed by personalized and precision 
medicine (Sorger et al., 2011; Musante et al., 2016). Ultimately, BE may be considered a modern 
contribution of chemical engineers to QSP. 
 
1.3. Physiologically-based Pharmacokinetic Models 
Recent studies of pharmacokinetics (PK) in mammals and, more specifically, in humans have 
required a multi, inter, and transdisciplinary approach (MITA). PK entails the dynamic 
quantification of administered drugs in the different organs and tissues of patients. In detail, drugs, 
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after administration, undergo the ADME (Absorption, Distribution, Metabolism, Excretion) 
processes through complicated pathways (ADME pathways) which are mediated by the 
anatomical and physiological characteristics of the mammalian body. A MITA to PK requires 
contributions from different perspectives and cultural backgrounds epitomized by physicians, 
pharmacists, biologists, chemists, and engineers (Ferrari et al., 2005). 
When engineers start to approach the PK subject, a large number of scientific publications guide 
them through rather complex phenomena which, from a mechanistic viewpoint, require deepening 
the understanding of both anatomy and physiology. Indeed, when one/two-compartment 
simplified models are taken into consideration (Wagner, 1993), an engineer may recognize their 
limitations in terms of modeling details and physical consistency with the human body. On the 
contrary, the introduction of an excessive number of details in the PK model (Jain et al., 1981) 
may lead to an overparameterized (98 adaptive parameters) and oversized (38 ordinary differential 
equations (ODE) and 21 compartments) model whose utility is constrained to one mammalian 
species (rats) and limited to one administration route (intravenous). In this context, 
physiologically-based pharmacokinetic (PBPK) models demonstrate their potential since they 
describe how the mammalian body follows ADME pathways. These models are based on an 
anatomical and physiological representation of organs and tissues interconnected by the 
circulatory and lymphatic systems. Engineers’ perception of the functioning of organs and tissues 
is always in terms of process units, unit operations, vessels, reactors, membranes, transport 
phenomena, ducts, inputs, outputs, recirculation, and efficiency. Hence, according to process 
engineers’ point of view, the mammalian body may be represented by a set of interconnected 
process units (compartments) exchanging mass flows and symbolizing either single or lumped 
organs/tissues (Di Muria et al., 2010; Del Cont et al., 2014). Some may be mathematically 
represented by perfectly mixed tanks/reactors (such as stomach, liver, gallbladder, and poorly 
perfused tissues which may lump different subsystems together), others may be assimilated to plug 
flow ducts/reactors such as the small and large intestinal lumina, where distributed mass flows 
cross the surrounding wall (i.e. the intestinal membrane) and deliver substances (i.e. nutrients and 
active principles) to the gastrointestinal circulatory system by means of two-way mass transfer 
coefficients. The mass transfer through the intestinal wall may be assumed as a diffusive 
phenomenon based on Fick’s law, but, in reality, the involved cellular membrane molecular 
exchange is more complicated than a passive gradient-driven mass transfer. The plug flow 
representation of the intestinal lumina may be further simplified into a suitable series of perfectly 
mixed tanks/reactors. Hence, the partial differential equations describing the spatiotemporal mass 
flows are discretized into finite difference equations and the translation into a system of ODE 
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renders the numerical solution easier and more efficient. At the same time, the organs/tissues, 
represented in terms of compartments and symbolized by an equivalent plant equipment, are 
interconnected by mass transfer pathways. The process flow diagram, which graphically shows 
the interconnected compartments, may also include recirculation, for instance, the enterohepatic 
circulation between gallbladder and duodenum through Oddi’s sphincter discussed by Abbiati and 
co-workers (Abbiati et al., 2015a). The periodic recirculation of bile from the gallbladder to the 
intestinal lumen is mediated by Oddi’s sphincter acting as a valve, thus opening and closing 
according to the feeding and digestive processes. The aforementioned entails the simulation of 
periodic batch, semi-batch, and continuous processes as a function of the specific compartment. 
Every patient may be characterized by a personalized PBPK model depending on sex, age, body 
mass index, and other factors. In order to consider these factors, the principal organs such as liver 
and kidneys may be characterized by a specific efficiency as catalysts, heat exchangers or 
separation units. The combination of these elements allows writing a series of dynamic mass 
balances around the nodes of the plant (i.e. compartments), thus obtaining an ODE system. Hence, 
the concentrations in organs and tissues are dependent variables to be integrated numerically in 
order to determine PK profiles involved in ADME phenomena. The input and output streams of 
the mammalian body are represented by administration routes and excretion pathways, 
respectively. The estimated organs/tissues concentrations constitute a valuable decision support 
tool for physicians, by allowing them to comprehend the distribution and metabolic pathways of 
drugs in patients and thus determine the amount of active principle per body mass and time unit to 
be dynamically administered in order to either shorten healing times or equalize the concentration 
distribution in the case of chronic diseases treatment (Abbiati et al., 2015b). 
 
1.4. Bioavailability Enhancement 
Bioavailability, defined as the rate and extent to which the active substance or the active moiety is 
absorbed from a pharmaceutical form and becomes available at the site of action (Pharmacos 4), 
depends on several factors, among which the drug solubility in an aqueous environment and the 
drug permeability across lipophilic membranes play a prominent role (Yu et al., 2000). Indeed, 
only dissolved molecules may be absorbed by cellular membranes, thus reaching the site of drug 
action (vascular system, for instance). Depending on solubility and permeability, drugs may be 
classified into four different classes (Amidon et al., 1995) and, therefore, a drug belonging in class 
IV (high solubility and permeability) is defined as bioavailable. Several techniques are commonly 
employed to improve the bioavailability of poorly water-soluble but permeable drugs (Perrett and 
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Venkatesh, 2006). In this sense, drug particle size reduction, drug encapsulation in the lipid matrix 
of nano/microspheres (Charman et al., 1992) or drug dissolution in the dispersed lipophilic phase 
of oil/water emulsions or microemulsions (Costantinides, 1995; Gasco, 1997; Pouton, 1997; 
Kumar and Mittal, 1999) may be mentioned. A similar goal is achievable through drug 
complexation with cyclodextrins in solution or in the presence of the molten drug. Finally, by 
means of solvent swelling, it is possible to load a drug in a nanocrystalline or amorphous state into 
a polymeric carrier, thus considerably increasing its bioavailability (Grassi et al., 2003; Dobetti et 
al., 2001). For instance, the simple particle size reduction by milling allowed reducing fenofibrate 
(Tricor®) dose from a standard drug 300 mg capsule to a bioequivalent 145 mg tablet containing 
nanocrystalline drug (Perrett and Venkatesh, 2006). Interesting examples of lipid-based 
formulations (either self-emulsifying or emulsifying due to the presence of bile salts) are antivirals 
– Norvir® (ritonavir) and Fortovase® (saquinavir) – and immunosuppressive cyclosporines –
Sandimmune® and Neoral®. While Fortovase® increased saquinavir bioavailability up to threefold 
with respect to the original Invirase® (saquinavir mesylate in powder form) (Roche), the reduction 
of emulsion particle size allowed Neoral® to be more bioavailable than the original Sandimmune® 
(Van Mourik et al., 1999). Cyclodextrins may be found in several marketed products such as 
Vfend® (voriconazole), Geodon® (ziprasidone mesylate), and Sporanox® (itraconazole). These 
solutions are intended for parenteral or oral use (Perrett and Venkatesh, 2006) and characterized 
by a high cyclodextrin/drug ratio (from approximately 15:1 to 40:1). Prograf® and Sporanox® 
capsules are successful examples of commercial applications of the solvent swelling technique 
(Ueda et al., US Patent; Gilis et al., US Patent). Obviously, each approach shows advantages and 
disadvantages and may be more suitable for a certain type of drug or a specific administration 
route. Mechanochemically activated systems, in particular, may be administered in the form of 
tablets or capsules, as both formulations preserve the “activated” state. In general, any formulation 
not requiring the employment of solvents or high temperatures may be in principle taken into 
consideration. For these reasons, mechanochemically activated systems are suitable for oral 
administration, the most common route for humans due to better patient compliance and versatility 
with regard to dosing conditions. Nevertheless, the mechanochemical and solvent swelling 
activation entails a considerable bioavailability improvement when the drug solubility in aqueous 
media is lower than 100 µg/cm3. 
 
1.5. Nanocrystals 
As the oral route has always been the simplest and most appreciated way to administer drugs, 
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many efforts were made in the past to render this administration also practicable for poorly water-
soluble drugs, which are usually characterized by low bioavailability (Grassi et al., 2007) and 
represent approximately 40% of the drugs in the development pipelines. In addition, up to 60% of 
synthesized compounds are poorly soluble (Lipinski, 2002) and 70% of potential drug candidates 
are discarded due to low bioavailability related to poor solubility in water (Cooper, 2010). 
Examples of commonly marketed poorly soluble drugs (water solubility less than 100 µg cm–3) 
include analgesics, cardiovasculars, hormones, antivirals, immunosuppressants, and antibiotics 
(Grassi et al., 2007). Thus far, an effective solution to increase the bioavailability of poorly soluble 
drugs has appeared to be nanonization, i.e. the pulverization of solid substances into the nanometer 
range, which dramatically increases the crystal surface-volume ratio and the solid-liquid interface. 
This immediately translates into the nanocrystals melting temperature (Tm) and enthalpy (∆Hm) 
reductions (Brun et al., 1973), which, in turn, is reflected in the increase of drug water solubility 
and, consequently, drug bioavailability. 
A valid explanation for this phenomenon is the different arrangement of the surface and bulk 
phases. Indeed, the surface atoms/molecules present fewer bonds than the bulk ones (Lubashenko, 
2010) and, accordingly, a higher energy content. Therefore, the surface lattice destruction 
necessitates less energy and is favored over the bulk one. Molecular dynamics (MD) simulations 
and experimental data regarding Au nanocrystals confirmed the previous theoretical analysis 
(Huang et al., 2008; Toledano and Toledano, 1987) by highlighting the different behavior of the 
surface and bulk atoms. In fact, the coherent electron patterns diffracted by single nanocrystals 
depend on the atomic structure of surfaces. This interpretation, valid for metals, may be also 
extended to organic substances (Jiang et al., 1999). Indeed, the fundamentally vibrational melting 
entropy of organic crystals implies that the organic molecules in crystalline arrangement behave 
analogously to metals. This indicates that the peculiar properties of organic nanocrystals may be 
investigated by means of the same theoretical models employed for metallic nanocrystals. Indeed, 
the melting entropy of organic crystals is essentially constituted by a vibrational component, which 
implies that the molecules in organic crystals exhibit a similarity to the atoms in metallic crystals. 
Accordingly, for molecular solids, the difference in activation energy between surface and bulk 
may be explained by a difference in molecular mobility (Jiang et al., 1999). Obviously, the surface 
atoms/molecules effect is macroscopically detectable only if their number is comparable to the 
bulk one, i.e. when the surface-volume ratio is no longer negligible as it happens in nanocrystals. 
Several researchers (Zhang et al., 2000) investigated both experimentally and theoretically the 
melting properties in connection with crystal size, whereas solubility dependence is still 
controversial due to experimental measurement difficulties (Grassi et al., 2007, Buckton and 
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Beezer, 1992). In particular, manufacturing processes, usually altering surface characteristics by 
introducing lattice defects, prevent the use of fine crystals for experimental solubility 
determinations (Mosharraf and Nyström, 2003). Little impurities are able to affect solubility and 
polydispersed crystals undergo Ostwald ripening (Madras and McCoy, 2003), the growth of larger 
crystals at the expense of the smaller ones, which leads to an asymptotic solubility diminution. 
Therefore, in the light of these considerable experimental difficulties, the theoretical determination 
of drug solubility as a function of nanocrystals size has become mandatory. Despite the previously 
discussed experimental issues, the manufacture of nanocrystal-based drug delivery systems is 
feasible without particular difficulties. For instance, solvent swelling (Carli et al., 1986; Grassi et 
al., 2000), supercritical carbon dioxide (Debenedetti et al., 1993; Kikic et al., 1999), cogrinding 
(Grassi et al., 1998; Voinovich et al., 2009; Hasa et al., 2011; Hasa et al., 2012; Coceani et al., 
2012), and cryomilling (Crowley and Zografi, 2002) allow the dispersion of the drug, in 
nanocrystalline or amorphous form, into a carrier, typically an amorphous cross-linked polymer 
(Colombo et al., 2009). Indeed, the polymer acts as a stabilizer for nanocrystalline/amorphous 
drugs, which otherwise would tend to recrystallize, thus returning to their more thermodynamically 
stable macrocrystalline state. The presence of drug and stabilizer generates a distribution of 
particles with different sizes, i.e. the secondary grains, composed of crystals, i.e. the primary 
grains, which are connected by an amorphous phase constituted by the amorphous drug and/or 
stabilizer. Furthermore, primary grains are constituted by short-range structural arrangements 
(crystallites), i.e. those coherent crystalline domains whose size is commonly referred to as crystal 
dimension (Colombo et al., 2009). The reliability and effectiveness of such delivery systems were 
proved by in vitro and in vivo tests, which revealed a considerable bioavailability improvement 
for poorly water-soluble but permeable drugs (Colombo et al., 2009; Meriani et al., 2004), 
otherwise known as class II drugs according to Amidon’s classification (Amidon et al., 1995). 
Traditionally, the peculiar properties of nanocrystals have been explored in metallurgy (Nanda, 
2009; Goswami and Nanda, 2012) and then in materials (Ha et al., 2004; Ha et al., 2005) and 
pharmaceutical sciences (Hamilton et al., 2012). In particular, Ha and co-workers (Ha et al., 2004), 
by studying the crystallization of anthranilic acid (AA) in nanoporous polymeric and vitreous 
matrices, were the first to report on the effect of nanoconfinement on organic polymorphic crystals. 
They demonstrated that polymorph selectivity during the sublimation of AA was influenced by 
the surface properties of glass substrates. Indeed, the preference for the metastable form II in 
smaller pores is assumed to be caused by a smaller critical nucleus size than the other two 
polymorphs (I and III). In another paper, Ha and co-workers (Ha et al., 2005), by examining the 
crystallization of organic compounds in nanochannels of controlled pore glass and porous 
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polystyrene, detected a clear Tm/∆Hm depression associated with the decreasing channel diameters, 
this being consistent with the increasing crystals surface/volume ratio. In addition, they realized 
that Tm depression also depends on the properties of the embedding matrix and this was explained 
with the different nanocrystals interactions with channel walls. While Zandavi demonstrated the 
validity of thermodynamics at least in pores down to a radius of 1.3 nm (Zandavi and Ward, 2013), 
Beiner and collaborators deepened the understanding of the effect of pores morphology on crystals 
polymorphism (Beiner et al., 2007) and the appearance of an amorphous drug layer between pore 
wall and nanocrystal surface due to drug-wall interactions (Rengarajan et al., 2008). Hasa (Hasa 
et al., 2016), Belenguer (Belenguer et al., 2016), and co-workers focused the attention on 
cocrystals. In particular, Hasa and co-workers (Hasa et al., 2016) explored how the amount of a 
specific liquid present during the liquid-assisted mechanochemical reactions may be exploited to 
rapidly investigate polymorphs diversity. Indeed, for the considered multicomponent crystalline 
system formed by caffeine and AA in a 1:1 stoichiometric ratio, only 4 out of 15 liquids were 
found to be highly selective for one polymorphic form, while the others produced more than one 
cocrystal polymorph depending on the amount of liquid used (the selected volume range was 10–
100 µL). A similar phenomenon was observed by Belenguer and co-workers (Belenguer et al., 
2016) while investigating two other (dimorphic) systems, namely 1:1 theophylline/benzamide 
cocrystals and an aromatic disulfide. Importantly, Belenguer and co-workers (Belenguer et al., 
2016) also provided a possible explanation for the different amounts of a liquid which produce 
different polymorphic forms. Indeed, such phenomenon was related to particle size: metastable 
polymorphs, as micrometer-sized or larger crystals, may often be thermodynamically stabilized at 
the nanoscale. Additionally, surface effects were reported to be significant in the polymorphism at 
the nanoscale and the outcomes of mechanochemical equilibrium experiments appeared to be, in 
general, controlled by thermodynamics. While Lee was able to measure amorphous ibuprofen 
solubility by resorting to nanoporous aluminum oxide (Lee et al., 2013), Beiner and his group 
proved that nanoconfinement is a strategy to produce and stabilize otherwise metastable or 
transient polymorphs of pharmaceuticals, as required by controllable and effective drug delivery 
(Graubner et al., 2014; Sonnenberger et al., 2016). Myerson and co-workers (Eral et al., 2014; 
Badruddoza et al., 2016) investigated the use of biocompatible alginate hydrogels as smart 
materials to crystallize and encapsulate different types of drugs (acetaminophen and fenofibrate). 
Interestingly, they discovered that hydrogels with smaller meshes appear to show faster nucleation 
kinetics. In addition, Myerson and co-workers (O’Mahony et al., 2015; Dwyer et al., 2017) 
employed controlled pore glass and porous silica supports to obtain nanocrystals of fenofibrate 
and griseofulvin, thus achieving an increased dissolution rate in comparison with that of the 
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original macrocrystals. 
 
1.6. Drug Activation 
In the light of what discussed thus far, the nanocrystalline and amorphous states may be considered 
an “activated” condition as they are characterized by an enhanced solubility (and thus 
bioavailability) with respect to the macrocrystals they originate from. The experimental 
verification of this activation falls into the broad field of the solid state characterization. Typically, 
the considered approach evaluates the macro, nanocrystalline or amorphous states of a drug 
embedded in an amorphous matrix acting as a stabilizer. Indeed, the nanocrystalline and 
amorphous states are unstable and tend to return to the original macrocrystalline condition. 
Accordingly, the techniques based on the difference of periodicity of the atoms in crystals (X-rays 
powder diffraction, XRPD), the energy of the bond stretching/bending and lattice vibrations 
(infrared, IR, and Raman spectroscopy), the electronic environment of nuclei (nuclear magnetic 
resonance, NMR), the thermal analysis of heat flow or weight change (differential scanning 
calorimetry, DSC, and thermal gravimetric analysis, TGA), and morphology (optical microscopy) 
may be useful for this purpose (Stephenson et al., 2001; Bugay, 2001). In particular, the solid state 
characterization serves to exclude the formation of new chemical species (the evidence of chemical 
reactions) or polymorphs raising regulatory issues. At the same time, this characterization is 
required to estimate the residual amount of crystalline drug (Xnc) after the activation treatment. 
Indeed, this parameter may be roughly regarded as a measure of drug activation. More precisely, 
a more proper evaluation of activation not only requires the determination of Xnc but also the size 
distribution of drug crystals. In addition to the aforementioned techniques, other approaches are 
able to provide an estimation of activation such as solution calorimetry, water sorption (Yu, 2001), 
and release tests (RT) (Grassi et al., 2007). 
The DSC characterization is based on the reduction of Tm/∆Hm with crystals size decrease. Indeed, 
at the nanoscale, crystals properties not only depend on bulk atoms/molecules but also on the 
surface ones. This is due to the fact that surface atoms show fewer interatomic bonds than the bulk 
ones, which makes the former more loosely bound than the latter (Zhang et al., 2000). The Tm 
reduction in nanosized particles was originally predicted by the thermodynamic nucleation theory 
in the early 1900s (Gibbs-Thomson’s equation) (Gibbs, 1928; Ha et al., 2005): 
( )θcos
ρ
γ4
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                                                                                                         (1.6.1) 
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where d is crystal diameter, γsl is solid-liquid surface tension, and θ represents the contact angle of 
the solid nanocrystal with the pore wall in the case of crystals confined in nanopores, being θ = 
180° (cos(θ) = –1) in the case of unconfined nanocrystals. 
When, at the moment of melting, a substance decomposes and/or solid phase interactions occur 
during heating, DSC is unable to detect the presence and abundance of crystals. In this case, a 
valid alternative is represented by XRPD provided that the amount of amorphous phase and/or 
adsorbed water is modest and the X-rays diffraction pattern is unaffected by considerable peak 
overlaps and the preferred orientation of the powder sample is meaningless. While a detailed 
description of the crystals abundance determination after drug/carrier grinding goes beyond the 
scopes of this chapter, it is interesting to recall its working equation (Bergese et al., 2003): 
( )[ ]α
∑
∑
= D
i
i0
i
i
D XfI
I
X                                                                                                               (1.6.2) 
where XD is the drug macro and nanocrystalline fraction in the ground mixture, Ii is the area of the 
ith peak belonging to the X-rays pattern, ∑
i
iI  and ∑
i
i0I  are, respectively, the sum of all peak 
areas characterizing the ground and original drug X-rays pattern, α is a semiempirical factor 
considering microabsorption effects, and f(XD) is a function of XD depending on the drug-carrier 
mixture. The unknowns α, f(XD), and ∑
i
i0I  may be calculated from a calibration procedure based 
on the measurement of several physical mixtures of the original crystalline drug and the carrier. 
While amorphous structures cause a broad diffraction owing to the lack of a long-range periodicity 
of the atomic arrangement, nanocrystalline materials entail a deviation from the X-rays diffraction 
pattern related to an ideal crystal since an atomic arrangement periodicity exists only over a few 
molecular distances. In particular, a finite crystallite size, strain, and extended defects (stacking 
faults, dislocations) lead to broadening diffraction peaks. In this context, the entire pattern profile 
modeling (peaks position, intensity, width, and shape) may provide a complete evaluation of the 
grains size distribution and lattice defects content (Grassi et al., 2007). The use of the so-called 
radial distribution function, evaluable from experimental patterns by means of Fourier’s transform, 
allows determining the probability of finding an atom at a given distance from the center of a 
reference atom of the system (Proffen et al., 2003). Very smooth and low noise experimental data 
are required to achieve reliable and reproducible results. For these reasons, synchrotron and 
similarly intense X-rays sources are recommended. An alternative approach to the analysis of 
diffraction data of amorphous materials is the one proposed by Luterotti and co-workers (Luterotti 
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et al., 1998). In this regard, crystallite size and microstrain were introduced to consider the 
diffraction peaks broadening of an amorphous structure. By reducing coherent scattering domains, 
the corresponding Bragg’s reflections broaden to such an extent that they produce a typical 
amorphous solids diffraction pattern (halo). Furthermore, in the pharmaceutical field, XRPD is 
able to provide further information concerning the drug-stabilizer system. Indeed, while drug 
activation is desirable, the formation of new chemical entities or polymorphs is undesirable, as 
their presence would lead to regulatory issues. Undoubtedly, the Food and Drug Administration 
(FDA) approval for the native drug is unextendable to the other chemical compounds produced by 
the process (solvent swelling, supercritical carbon dioxide, cogrinding, and cryomilling) 
considered to obtain drug activation. In this context, XRPD plays a crucial role, as the formation 
of polymorphs or the occurrence of chemical transformations is reflected in evident differences 
between the XRPD pattern of the native and activated drug. 
The drug release test on activated systems is another excellent method to evaluate the activation 
level, although the determination of the crystalline, nanocrystalline, and amorphous drug 
abundance is indirect by interpreting experimental data by means of proper mathematical models 
(Grassi et al., 2007). Unfortunately, a unifying model which describes the drug release from every 
activated system is unavailable, as release kinetics also depends on the considered carrier 
(stabilizer). In this regard, carriers may be approximately divided into two main classes: the cross-
linked polymers and the remaining ones. This classification is motivated by the fact that, in the 
second case, drug-carrier interactions develop superficially through more or less complex 
adsorption/desorption mechanisms, while, in the first case (cross-linked polymers), the topological 
properties of the carrier are also able to play a key role, as the drug may be embedded in the (stable) 
polymeric network. Accordingly, both the drug diffusion into the (swelling) network and drug-
polymer interactions affect release kinetics. Besides these mechanisms, the crystalline, 
nanocrystalline, and amorphous drug dissolution in the release medium also rules release kinetics. 
Indeed, after contacting the external release medium, the stabilizing action exerted by the carrier 
vanishes (obviously, by following different kinetics depending on the carrier type) and the drug 
starts dissolving with the possible formation of macrocrystals and/or polymorphs. As drug 
solubility depends on crystal dimension (the amorphous phase may be regarded as crystals of 
vanishingly small dimensions), the release process may occur due to the time-dependent drug 
solubility (Grassi et al., 2007). One of the most common equations used to describe this particular 
behavior is Nogami’s (Nogami et al., 1969): 
( ) ( ) mcmcnca,s re CCCtC tK +−= −                                                                                                 (1.6.3) 
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where Cs is the time (t) dependent drug solubility, Kr is the recrystallization constant, Ca,nc 
represents the amorphous or nanocrystalline drug solubility, while Cmc indicates the solubility of 
macrocrystals. This equation states that, at the beginning (t = 0), Cs equals Ca,nc and then decreases 
exponentially, thus reaching Cmc. Obviously, eq 1.6.3 intrinsically takes account of macrocrystals 
dissolution (those not undergoing recrystallization phenomena). Indeed, their dissolution is 
represented by eq 1.6.3 when Kr = ∞ (Cs is then always equal to Cmc). Accordingly, the general 
dissolution equation becomes: 
( )[ ]CtCK
t
C
−−=
∂
∂
s
nca,
t
nca,
                                                                                                        (1.6.4) 
where nca,tK  indicates the amorphous or nanocrystalline drug dissolution constant. Obviously, eq 
1.6.4 may be written for the amorphous, nanocrystalline, and macrocrystalline drugs. The 
contribution of each equation to the global dissolution rate depends on the relative abundance of 
each form. By associating eq 1.6.4 with a proper equation considering the drug diffusion across 
the polymeric network, the final mathematical model able to interpret experimental data is 
obtained. 
Experimentally, release tests may be performed in the sink or non-sink conditions according to the 
usual dissolution testing procedures. While, in sink conditions, higher activation levels are 
reflected in higher release kinetics, the adoption of non-sink conditions allows observing a peculiar 
release pattern. Indeed, due to the conversion of the amorphous drug into the more stable 
macrocrystalline form implying a drug solubility reduction, the release concentration curve may 
display a rapid increase followed by a decrease. 
 
1.7. Aim 
In the previously delineated context, the attention of the present doctoral thesis was turned to drug 
nanocrystals embedded/mixed in/with cross-linked polymeric microparticles acting as a stabilizer 
for nanocrystalline and amorphous drugs (Colombo et al., 2009). Owing to their low water 
solubility, good permeability, and relevance to the pharmaceutical industry (Grassi et al., 2007; 
Davis and Brogden, 1994), nimesulide, griseofulvin, and nifedipine, three typical poorly water-
soluble drugs, were selected as a proof of concept in the present study. 
Thus far, the majority of theoretical approaches have been devoted to investigating the relation 
existing between spherical nanocrystals size and Tm/∆Hm, while only a few of them considered 
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non-spherical shapes (Nanda, 2009). Moreover, these last ones were focused on metallic 
nanocrystals and none of them on drug nanocrystals. It seems that no study aimed at elucidating 
the effect of nanocrystals shape on the reduction of Tm/∆Hm and the consequent increase of 
solubility is present in the literature until now. Accordingly, this thesis attempted to theoretically 
study the dependence of Tm/∆Hm decrease on nanocrystals size by means of a thermodynamic 
model considering crystals shape (sphere, cylinder, parallelepiped). The outcomes of this model 
were validated by the corresponding ones obtained from molecular dynamics simulations as a 
function of drug crystal shape and size. Finally, the information acquired from the developed 
thermodynamic model was embodied in another mathematical model dedicated to describing the 
drug release from an ensemble of polydispersed polymeric particles administered following the 
oral route. Therefore, this model could describe the simultaneous processes of drug release and 
drug absorption by living tissues and allow evaluating the effect of nanocrystals. 
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CHAPTER 2 
 
THERMODYNAMIC MODEL 
 
 
2.1. Physical Frame 
At the beginning of the last century, Tm decrease by means of crystal size reduction was 
thermodynamically predicted and experimentally demonstrated (Pawlow, 1909). Afterward, 
several researchers developed theoretical models to explain Tm/∆Hm depression phenomenon 
accompanying crystals size decrease. Among them, the thermodynamic ones (Nanda, 2009; 
Sdobnyakov et al., 2008) 
Rv
Vapor
Rs
Solid
Rl
Liquid
Liquid Skin Melting
Rv
Rs
Solid
Rl
Liquid
Vapor
Liquid Nucleation and Growth
Rv
Vapor
Rs
Solid
Rl
Liquid
Homogenous Melting
 
Figure 2.1. Thermodynamic models of nanocrystals melting are based on three mechanisms: 
Homogeneous Melting, Liquid Skin Melting, Liquid Nucleation and Growth. Rv, Rl, and Rs are the 
vapor, liquid, and solid phases radii, respectively. 
 
Sdobnyakov et al., 2008) were confirmed by MD simulations and were potentially able to describe 
different crystal shapes. Furthermore, these models are well adapted to describe the phenomena 
involved in the drug melting process. Fundamentally, the thermodynamic models rely on the three 
physical schemes shown in Figure 2.1 (Nanda, 2009). The homogeneous melting (HM) approach 
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assumes the equilibrium between the solid and liquid drug phases that share the same mass and lie 
in the vapor phase. The liquid skin melting (LSM) theory presupposes the formation of a thin 
liquid layer over the solid core. The thickness of the liquid layer remains constant until the solid 
core completely melts. According to the liquid nucleation and growth (LNG) approach, on the 
contrary, the liquid layer thickness grows while approaching Tm. The solid core melting occurs 
when the liquid layer thickness is no longer negligible in comparison to the solid core size. 
Despite the fact that, theoretically, there are no reasons for preferring one of the three mechanisms 
depicted in Figure 2.1 (HM, LSM, LNG), two distinct physical considerations are in favor of the 
LSM and LNG approaches. The first one relies on the direct observation of drug crystals melting 
which shows the formation of a liquid shell around the solid phase before the occurrence of 
complete melting (hot stage microscopy approach). The second one is strictly related to a 
particularly interesting application of nanocrystals, i.e. the controlled delivery of drugs (the main 
focus of this thesis), where delivery systems relying on drug nanocrystals-polymer mixtures are 
often employed. Indeed, regardless of the drug loading technique considered to prepare drug-
polymer mixtures (solvent swelling, supercritical carbon dioxide, co-grinding, and cryomilling), 
the coexistence of drug nanocrystals and amorphous drug inside the polymeric matrix is usually 
observed (Bergese et al., 2004; Bergese et al., 2005). Thus, when the ratio between the amount of 
nanocrystalline drug and amorphous drug is very high (i.e. when nanocrystals mass fraction (Xnc) 
is close to one), drug melting should occur according to the physical description of the LSM 
approach. On the contrary, when Xnc approaches zero, i.e. when few nanocrystals melt inside an 
amorphous drug rich environment, the LNG theory appears to describe the melting process 
properly. Indeed, in this case, nanocrystals melting occurs in contact with a conspicuous drug 
liquid phase as, regardless of nanocrystal size, melting occurs at a higher temperature than the 
glass transition temperature of the amorphous drug, a value over which the amorphous drug is 
liquid and able to flow. Accordingly, it appears reasonable to presume that, when melting occurs, 
the thickness of the liquid layer surrounding the solid core is no longer negligible in comparison 
to the solid core one. 
 
2.2. Mathematical Frame 
The starting point for the three melting mechanisms is the definition of the infinitesimal reversible 
variation of the internal energy (E) for a closed system composed of k components and three phases 
(s solid, l liquid, v vapor) (Adamson and Gast, 1997): 
lvsvvls dddddd EEEEEE ++++=           HM                                                                                  (2.1a) 
2-3 
 
lvslvls dddddd EEEEEE ++++=            LNG/LSM                                                               (2.1b) 
where , , , , , slsvvls EEEEE  and lvE  represent the solid, liquid, vapor, solid/vapor, solid/liquid, and 
liquid/vapor phase internal energy, respectively. The expressions of the internal energy for the 
bulk and interfacial phases are given, respectively, by: 
bb
1i
b
i
b
i
bbb ddµdd VPnSTE
k
−+= ∑
=
                                                                                              (2.2) 
f
2
f
2
f
1
f
1
ff
1i
f
i
f
i
fff dddγdµdd cCcCAnSTE
k
++++= ∑
=
                                                                     (2.3) 
where the superscript “b” stands for bulk phase “s, l, or v”, the superscript “f” stands for interfacial 
phase “sv, sl, or lv”, T is temperature, S is entropy, iµ  and in  are, respectively, the chemical 
potential and the number of moles of the i-th component in each bulk/interfacial phase, P is 
pressure, V is volume, fγ  and fA  are, respectively, the surface tension and the area of the interface 
f, f1c  and 
f
2c  are the first and the second curvature referring to the interface f, while 
f
1C  and 
f
2C  
are the related constants. In order to transform eqs 2.1a and 2.1b into an operative model able to 
relate Tm to crystal radius, some hypotheses are required (Adamson and Gast, 1997): 
a) the contribution of the first and the second curvature to the system internal energy is negligible 
(this is strictly true for planes and spheres); 
b) the system composed of the solid, liquid, and vapor phases is closed (no matter or energy 
exchanges with the surroundings, i.e. system volume, entropy, and moles number are 
constant); 
c) thermal and chemical equilibrium is attained among the bulk and surface phases (same 
temperature and chemical potential for all components in all bulk and surface phases). 
Accordingly, eqs 2.1a and 2.1b may be rewritten as: 
lvlvsvsvvvllss dγdγdddd AAVPVPVPE ++−−−=           HM                                                   (2.4a) 
lvlvslslvvllss dγdγdddd AAVPVPVPE ++−−−=             LNG/LSM                                       (2.4b) 
By remembering the closed system condition (hypothesis (b): 0ddd vls =++ VVV ), the first three 
terms of eqs 2.4a and 2.4b right-hand sides become: 
( ) ( ) ( ) llvssvlsvllss dddddd VPPVPPVVPVPVP −+−=++−−             HM                          (2.5a) 
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( ) ( ) ( ) vvlsslvvvslss dddddd VPPVPPVPVVPVP −+−=−++−           LNG/LSM               (2.5b) 
Therefore, eqs 2.4a and 2.4b may be rewritten as: 
( ) ( ) lvlvsvsvllvssv dγdγddd AAVPPVPPE ++−+−=           HM                                               (2.6a) 
( ) ( ) lvlvslslvvlssl dγdγddd AAVPPVPPE ++−+−=            LNG/LSM                                    (2.6b) 
The condition of minimal energy ( 0d =E ) allows establishing the mechanical equilibrium among 
phases: 
s
sv
svvs
d
d
γ
V
APP =−                                                                                                                       (2.7) 
l
lv
lvvl
d
d
γ
V
APP =−                                                                                                                        (2.8) 
s
sl
slls
d
d
γ
V
APP =−                                                                                                                         (2.9) 
v
lv
lvlv
d
d
γ
V
APP =−                                                                                                                     (2.10) 
or in differential terms: 
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

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γddd
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APP                                                                                                           (2.11) 

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
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+= l
lv
lvvl
d
d
γddd
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APP                                                                                                            (2.12) 






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s
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slls
d
d
γddd
V
APP                                                                                                             (2.13) 






+=
v
lv
lvlv
d
d
γddd
V
APP                                                                                                            (2.14) 
In the case of a system constituted by one component only (i.e. the focus of this work), Gibbs-
Duhem’s equations for the solid, liquid, and vapor phases become: 
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0ddµd ss1
s
=−+ PvTs           solid                                                                                           (2.15) 
0ddµd ll1
l
=−+ PvTs             liquid                                                                                         (2.16) 
0ddµd vv1
v
=−+ PvTs          vapor                                                                                         (2.17) 
where s and v represent the molar entropy and volume referred to each bulk phase (solid, liquid, 
and vapor), while µ1 is the chemical potential of the only component constituting the three bulk 
phases (solid, liquid, and vapor). By subtracting eq 2.16 from eq 2.15 and eq 2.17 from eqs 2.15 
and 2.16 leads to: 
( ) 0ddd llssls =+−− PvPvTss                                                                                                            (2.18) 
( ) 0ddd vvssvs =+−− PvPvTss                                                                                                           (2.19) 
( ) 0ddd vvllvl =+−− PvPvTss                                                                                                           (2.20) 
Equations 2.13 and 2.14 insertion into eqs 2.18 and 2.20 yields to: 

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Then, eqs 2.11 and 2.12 insertion into eqs 2.19 and 2.20 leads to: 
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By equating the right-hand side term of eq 2.23 with that of eq 2.24 and doing the same for eqs 
2.21 and 2.22 yield to: 
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Equations 2.25a and 2.25b connect triple point temperature variation with interfacial properties. 
By further defining the difference ( sl ss − ) as the molar melting entropy mmm /Ths ∆=∆ , the 
working equation connecting mT  with the molar melting enthalpy ( mh∆ ) is obtained: 


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v
T
Th                     HM                                                       (2.26a) 
as sv  and lv  may be supposed to be negligible in comparison to vv  (Brun et al., 1973), and: 
( ) 
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since ls
ls
vl
vl
vv
ss
vv
ss
−
−
<<
−
−
 and 1lv
v
≈
− vv
v
. 
If the specific melting enthalpy is referred to the unit mass ( mH∆ ), eqs 2.26a and 2.26b become: 
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where sρ  and lρ  are, respectively, the solid and liquid phases density. 
Equations 2.27a and 2.27b should be adapted to consider the different geometrical shapes (sphere, 
cylinder, parallelepiped) chosen to approximate crystals shape. In particular, this adaptation 
regards the derivatives dAlv/dVl, dAsv/dVs, dAlv/dVv, and dAsl/dVs. Interestingly, by assuming that 
ρs and ρl are equal, considering spherical crystals, remembering Young’s equation for a pure 
substance (γsl + γlv = γsv) (Adamson and Gast 1997), regarding γsl and γlv as independent of 
curvature and ∆Hm as independent of temperature, the integration of eqs 2.27a and 2.27b returns 
the well-known Gibbs-Thomson’s equation (Gibbs, 1928; Ha et al., 2005): 
( )θcos
ρ
γ4
ms
sl
m
m
dHT
T
∆
−=
∆
                                                                                                                      (2.28) 
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where d is crystal diameter and θ represents the contact angle of the solid nanocrystal with the 
pore wall in the case of crystals confined in nanopores. In the case of unconfined nanocrystals (i.e. 
the situation considered in this work), cos(θ) = –1 (θ = 180°). 
In the following sections, eq 2.27b is particularized for differently shaped nanocrystals (sphere, 
parallelepiped, and cylinder). Although the same procedure may be also performed for eq 2.27a, 
it was decided not to consider that approach on the basis of the reasons exposed in the last part of 
section 2.1 and owing to the feeling that eq 2.27b is more general than eq 2.27a. Indeed, if no 
hypotheses are attempted on the spatial disposition of the three bulk phases, the infinitesimal 
reversible variation of the internal energy (E) becomes: 
lvslsvvls ddddddd EEEEEEE +++++=                                                                                (2.29) 
Equation 2.29 manipulation according to the same hypotheses and procedures applied to eq 2.1a 
and eq 2.1b leads to the following expression: 
lvlvslslsvsvllssvv ddddddd AγAγAγVPVPVPE +++−−−=                                                            (2.30) 
The closed system hypothesis allows concluding that the first three terms of eq 2.30 right-hand 
side become: 
( ) ( ) ( )lslvsvllvlsvv dddddd PPVPPVVPVVPVP −+−=−++−                                           (2.31) 
By substituting the pressure drop between the solid and vapor phases ( vs PP − ) with the obvious 
relation ( vllsvs PPPPPP −+−=− ), eq 2.31 becomes:  
( ) ( ) ( ) ( ) ( )vlvlsslslvlvlsv ddddd PPVPPVPPVPPVPPV −+−−=−+−+−                          (2.32) 
By introducing eq 2.32 into eq 2.30 and remembering Young’s equation for a pure substance (γsl 
+ γlv = γsv) (Adamson and Gast, 1997), the following relation is obtained: 
( ) ( ) ( ) ( )svlvlvsvslslvlvlss ddddd AAγAAγPPVPPVE ++++−+−−=                                            (2.33) 
The minimal energy condition (dE = 0) allows establishing the mechanical equilibrium ones: 
( ) ( )
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or, in differential terms: 
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where As and Av are, respectively, the area of the solid and vapor interfaces. By introducing eqs 
2.36 and 2.37 into Gibbs-Duhem’s equations (eqs 2.18 and 2.20), the following ones are obtained: 
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Equating the right-hand side terms of eqs (2.38) – (2.39) and rearranging them lead to: 
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By proceeding as for eqs 2.26a and 2.26b (νl and νs negligible compared with νv), eq 2.40 becomes: 
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




−





−=∆
s
s
sls
v
v
lvls
m
m
m d
dd
d
ddd
V
A
γv
V
A
γvv
T
Th                                                                          (2.41) 
or, if the specific enthalpy per unit mass is considered (∆Hm): 
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It is easy to verify that eq 2.42 coincides with eq 2.27b when Av and As are replaced, respectively, 
with Alv and Asl, i.e. the physical meaning of the vapor and solid interfaces when the phases 
disposition is the one assumed by the LNG/LSM mechanisms. 
 
2.2.1. Spheres 
By assuming crystals to be spherical (see Figure 2.1), it is possible to evaluate the two derivatives 
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dAlv/dVv and dAsl/dVs required by eq 2.27b: 
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where Rs, Rl, and Rv represent the radius of the solid, liquid, and vapor phases, respectively. While 
performing the two derivatives, the volume ( 3v34 πR ) is assumed constant. Moreover, Tolman’s 
equation was considered to take into account the surface energy dependence on surface curvature 
(Tolman, 1949; Samsonov et al., 2004; Lu et al., 2007; Jiang et al., 1999): 
1
02δ1
γ
γ
−
∞





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r
                                                                                                                  (2.2.1.3) 
where γ and γ∞ are the energy of a surface with curvature radius r and that of a flat surface (infinite 
curvature radius), respectively, while δ0 is Tolman’s length whose order of magnitude should 
correspond to the actual diameter (dm) of the molecules constituting the bulk phase and is usually 
assumed to be dm/3 (Rowlinson and Windom, 1982). Equation 2.2.1.3 predicts that surface energy 
tends to zero for low values of r. Thus, according to eqs 2.2.1.1
 
–
 
2.2.1.3, eq 2.27b becomes: 
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where lvγ
∞
 and slγ
∞
 are the surface energy of the plane liquid/vapor and solid/liquid interfaces, 
respectively. 
It is now necessary to express the dependence of Rl on Rs by adopting the strategy conceived by 
Coceani (Coceani et al., 2012). This approach relies on the fact that, very often, drug nanocrystals 
melting occurs in the presence of the amorphous drug that becomes liquid considerably before 
them. Indeed, as the glass transition temperature of the amorphous drug is lower than nanocrystals 
melting temperature, the amorphous drug will be liquid before nanocrystals melting. Thus, at the 
melting point, Xnc (drug nanocrystals mass/drug total mass) may be evaluated as: 
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Equation 2.2.1.5 allows obtaining the following parameter representing the ratio between Rl and 
Rs: 
3
nc
nc
l
s
s
l 11
ρ
ρ
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
 −
==α
X
X
R
R
                                                                                                (2.2.1.6) 
Obviously, while eq 2.2.1.5 strictly holds for a monodispersed nanocrystals size distribution, it on 
average holds for a polydispersed one. It is easy to verify that the LSM condition occurs when Xnc 
tends to 1 (the amorphous/liquid phase is virtually absent; Rl ≈ Rs), while the LNG condition takes 
place for Xnc near 0 (nanocrystals melting occurs in a virtually infinite liquid phase; Rl ≈ ∞). Thus, 
eq 2.2.1.4 may be rewritten as: 
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By assuming both ρs and ρl constant and independent of Rs, the integration of eq 2.2.1.7 between 
the melting temperature of the infinite radius crystal (Tm∞) and the melting temperature of the one 
with radius Rs (Tm) allows finding the working equation holding for spheres: 
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In order to solve eq 2.2.1.8 and obtain Tm dependence on Rs, it is necessary to evaluate ∆Hm 
dependence on Tm (see the integral in eq 2.2.1.8). In this context, the classic thermodynamic 
approach employed by Zhang and co-workers, holding regardless of nanocrystals nature (organic 
or inorganic) and being characterized by easily determinable parameters, may be considered 
(Zhang et al., 2000). This approach relies on a thermodynamic cycle (see Figure 2.2) according to 
which ∆Hm is calculated as the sum of five different contributions. The first is due to the 
aggregation of nanospheres with radius Rs into the bulk phase at nanocrystals melting temperature 
Tm (∆H1). In performing the evaluation of ∆H1, the surface energy of the bulk phase is implicitly 
assumed to be negligible in comparison to the original nanospheres one as the bulk phase surface 
is vanishingly small compared to that of nanospheres. The second implies the bulk phase heating 
from Tm to the infinitely large crystal melting temperature Tm∞ (∆H2), while the third represents 
the bulk phase melting at Tm∞ (∆H3). The fourth implies the bulk liquid disintegration into liquid 
nanospheres with radius Rs at Tm∞ (∆H4). Similarly, as in the aggregation of nanospheres (step 1), 
the surface energy of the bulk liquid phase is considered negligible in comparison to that of liquid 
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nanodrops. Finally, the fifth is the cooling of liquid nanodrops from Tm∞ to nanocrystals melting 
temperature Tm (∆H5): 
 
Figure 2.2. Thermodynamic cycle employed to derive eq 2.2.1.9. T is absolute temperature, P is 
pressure, Tm and ∆Hm are, respectively, nanocrystals melting temperature and enthalpy, Tm∞ and 
∆Hm∞ are, respectively, macrocrystals melting temperature and enthalpy, Vs and Asv are, 
respectively, solid phase volume and area of the solid-vapor interface referring to the ensemble of 
spheres with radius Rs, Vl and Alv are, respectively, liquid phase volume and area of the liquid-
vapor interface referring to the ensemble of spheres with radius Rs, γsv and γlv are, respectively, 
solid-vapor and liquid-vapor interface energies, sPC  and 
l
PC  are, respectively, specific heat at 
constant pressure relative to solid and liquid phases, while ρs and ρl are, respectively, density of 
the solid and liquid phases. 
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where ∆Hm∞ is the specific melting enthalpy of an infinitely large crystal, Vs and Asv are, 
respectively, the solid phase volume and the area of the solid-vapor interface referring to the 
ensemble of spheres with radius Rs, Vl and Alv are, respectively, the liquid phase volume and the 
area of the liquid-vapor interface referring to the ensemble of spheres with radius Rs, while sPC  
and lPC  are, respectively, the solid and liquid drug specific heat capacities at constant pressure. By 
remembering that Asv/Vs = 3/Rs, Alv/Vl = 3/Rs, γsv and γlv depend on surface curvature (1/Rs) 
according to Tolman’s theory (eq 2.2.1.3), and the difference between sPC  and lPC  is almost 
temperature independent (Hasa et al., 2013), eq 2.2.1.9 finally reads: 
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where svγ
∞
 is the surface energy of the plane solid/vapor interface. 
The melting properties dependence on nanospheres radius Rs (Tm(Rs); ∆Hm(Rs)) is achieved by the 
simultaneous numerical solution of eqs 2.2.1.8 and 2.2.1.10. By assuming that ∆Hm is constant in 
the temperature interval (Tm∞; Tm1 = Tm∞ – ∆T), eq 2.2.1.8 reads: 
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Consequently, the first estimation of ∆Hm1 according to eq 2.2.1.11 is: 
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By equating this ∆Hm1 estimation to the Zhang’s one (eq 2.2.1.10), it is possible to determine the 
value of Rs1 related to Tm1: 
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Rs1 is determined according to Newton’s method by assuming a relative tolerance of 10–6. Once 
Rs1 is known, ∆Hm1 may be evaluated according to eq 2.2.1.8 or eq 2.2.1.10. By repeating the same 
strategy for further melting temperature reductions (Tm – i∆T), the following general equation for 
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Rsi is achieved: 
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Similarly, after finding Rsi, ∆Hmi may be evaluated according to eq 2.2.1.8 or eq 2.2.1.10. In order 
to ensure the reliability of the numerical procedure, ∆T was set equal to 0.1 K. 
 
2.2.2. Parallelepipeds 
 
Figure 2.3. Spatial disposition of the three drug phases (solid, liquid, and vapor) according to the 
LNG and LSM theories. as, bs, and cs represent the three dimensions of the parallelepiped solid 
core, δ is the thickness of the surrounding liquid layer, while av, bv, and cv are the three dimensions 
of the vapor phase. 
 
While it is reasonable and physically sound that, in the case of a spherical crystal, the liquid phase 
is represented by a spherical shell (see Figure 2.1), the shape assumed by the liquid phase around 
the solid parallelepiped, on the contrary, is less obvious. However, for the sake of simplicity, it is 
usual to assume that the shape of the liquid phase is the same as the solid one (Sar et al., 2008). 
Accordingly, Figure 2.3, borrowing, for a parallelepiped, the physical situation depicted in Figure 
2.1, allows evaluating the analytical expression of the two derivatives dAlv/dVv and dAsl/dVs: 
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where as, bs, cs, av, bv, and cv represent the three dimensions of the solid and vapor phases, 
respectively, δ is the thickness of the surrounding liquid layer, ∆ = δ/as, β = bs/as, and ξ = cs/as. 
While performing the two derivatives, the volume (avbvcv) is assumed constant. Hence, by 
assuming that surface energy is the same for each parallelepiped face, eq 2.27b becomes: 
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In order to evaluate the ratio ∆, it is convenient to recall the definition of Xnc (drug nanocrystals 
mass/drug total mass): 
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Equation 2.2.2.4 inversion allows the determination of the function ∆(Xnc): 
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The numerical solution of eq 2.2.2.5 (Newton’s method) enables the evaluation of the parameter 
∆ required by eq 2.2.2.3. By assuming both ρs and ρl constant and independent of as, the integration 
of eq 2.2.2.3 from the melting temperature of the infinitely large crystal (Tm∞) to the melting 
temperature of the nanocrystal with size as (Tm), allows finding the working equation holding for 
parallelepipeds: 
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Implicitly, eq 2.2.2.6 implies that surface energy (both lvγ
∞
 and slγ
∞
) is independent of crystal shape 
(β, ξ), dimension (as), and crystal facet. As a matter of fact, this assumption is sometimes 
unverified, as nicely documented by Heng and co-workers (Heng et al., 2006) who proved that 
paracetamol form I crystals exhibit different solid/vapor surface energies on distinct crystal facets. 
In this particular case, the explanation for this occurrence was the variable number of hydroxyl 
groups present on crystal facets. It is worth mentioning that, in principle, the derivation of eq 
2.2.2.6 could also consider the surface energy dependence on crystal shape, dimension, and facet. 
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In particular, in order to take account of the surface energy dependence on crystal facet, eq 2.2.2.6 
modification is relatively straightforward provided that the surface energy pertaining to each facet 
is available: 
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are, respectively, 
the surface energy of each liquid/vapor and solid/liquid flat interface. It is easy to verify that if all 
liquid and solid facets are characterized by the same surface energy ( lvγ
∞
 and slγ
∞
, respectively), eq 
2.2.2.6 is returned. Moreover, while it is more probable that solid facets are characterized by 
different surface energies, this is an unlikely occurrence for “liquid facets”. Indeed, as already 
mentioned (Heng et al., 2006), different values of slγ
∞
 may be owed to an anisotropic spatial 
distribution of atoms/molecules inside a crystalline network. On the contrary, this explanation 
appears to be far less plausible inside a liquid phase owing to the lack of a crystalline order. 
Accordingly, although eq 2.2.2.7 is more general, the differentiation of lvγ
∞
 is commonly 
unnecessary.  
Similarly, eq 2.2.2.6 solution requires the evaluation of ∆Hm on Tm (see the integral in eq 2.2.2.6) 
and Zhang’s approach may be used (Zhang et al., 2000). With the same hypotheses of eq 2.2.1.9, 
Zhang’s equation for parallelepipeds reads: 
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where Vs and Asv are, respectively, the solid phase volume and the area of the solid-vapor interface 
referring to the ensemble of parallelepipeds with dimensions as, bs, cs, Vl and Alv are, respectively, 
the liquid phase volume and the area of the liquid-vapor interface referring to the ensemble of 
parallelepipeds with dimensions as, bs, cs. 
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The melting properties dependence on nanoparallelepipeds size as (Tm(as); ∆Hm(as)) is achieved 
by the simultaneous numerical solution of eqs 2.2.2.6 and 2.2.2.8. By assuming that ∆Hm is 
constant in the temperature interval (Tm∞; Tm1 = Tm∞ – ∆T), eq 2.2.2.6 reads: 
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Consequently, the first estimation of ∆Hm1 according to eq 2.2.2.9 is: 
( ) 










+++





+
+
+
+
+






−−=∆ ∞
∞
∞
ξ
1
β
11
ρ
γ
2∆ξ
1
2∆β
1
∆21
1
ρ
1
ρ
1
γ
ln3
4
s
sl
ls
lv
m1ms1
m1 TTa
H (2.2.2.10) 
By equating this ∆Hm1 estimation to the Zhang’s one (eq 2.2.2.8), it is possible to determine the 
value of as1 related to Tm1: 
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(2.2.2.11) 
Once as1 is known, ∆Hm1 may be evaluated according to eq 2.2.2.6 or eq 2.2.2.8. By repeating the 
same strategy for further reductions of Tm, the following general expression for asi is achieved: 
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(2.2.2.12) 
Similarly, after finding asi, ∆Hmi may be evaluated according to eq 2.2.2.6 or eq 2.2.2.8. In order 
to ensure the reliability of the numerical procedure, ∆T was set equal to 0.1 K. 
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2.2.3. Cylinders 
 
Figure 2.4. Spatial disposition of the three drug phases (solid, liquid and vapor) according to the 
LNG and LSM theories. Rs and Ls represent the radius and the length of the cylinder solid core, 
respectively, δ is the thickness of the surrounding liquid layer, while Rv and Lv are the radius and 
the length of the vapor phase, respectively. 
 
By following the same strategy adopted for parallelepipeds, the two derivatives dAlv/dVv and 
dAsl/dVs become, for cylindrical crystals (see Figure 2.4): 
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where Rs, Ls, Rv, and Lv represent the radius and the length of the solid and vapor phases, 
respectively, δ is the thickness of the surrounding liquid layer, ∆ = δ/Rs, and λ = Ls/Rs. While 
performing the two derivatives, the volume vvπ LR
2
 is assumed constant. 
For cylindrical crystals, particular attention should be paid to the expression of the interface energy 
as, while assuming the lateral surface of the cylinder chemically and physically equal to the two 
bases, the different curvature of the bases (infinite curvature) and the lateral surface (curvature = 
1/Rs) should be considered. Hence, according to eqs 2.2.3.1, 2.2.3.2, and 2.2.1.3, eq 2.27b 
becomes: 
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Similarly, ∆ may be evaluated by resorting to Xnc (drug nanocrystals mass/drug total mass): 
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The numerical solution (Newton’s method) of eq 2.2.3.5 allows determining the parameter ∆ 
required by eq 2.2.3.3. By assuming both ρs and ρl independent of Rs, the integration of eq 2.2.3.3 
from the melting temperature of the infinitely large crystal (Tm∞) to the one of the nanocrystal with 
radius Rs (Tm) allows finding the working equation holding for cylinders: 
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Similarly, eq 2.2.3.6 solution requires the evaluation of ∆Hm on Tm (see the integral in eq 2.2.3.6) 
and Zhang’s approach may be used (Zhang et al., 2000). With the same hypotheses of eq 2.2.1.9, 
Zhang’s equation for cylinders reads: 
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where Vs and Asv are the solid phase volume and the area of the solid-vapor interface referring to 
the ensemble of cylinders with radius Rs and length Ls, respectively, while Vl and Alv are the liquid 
phase volume and the area of the liquid-vapor interface referring to the ensemble of cylinders with 
radius Rs and length Ls, respectively. Equations 2.2.3.6 and 2.2.3.7 inspection reveals that the 
reduction of surface energy ( sllv   γ,γ ) with cylinder radius (see eq 2.2.1.3) implies a smaller 
decrease of both ∆Hm and Tm. 
The melting properties dependence on nanocylinders radius Rs (Tm(Rs); ∆Hm(Rs)) is achieved by 
the simultaneous numerical solution of eqs 2.2.3.6 and 2.2.3.7. By assuming that ∆Hm is constant 
in the temperature interval (Tm∞; Tm1 = Tm∞ – ∆T), eq 2.2.3.6 reads: 
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Consequently, the first estimation of ∆Hm1 according to eq 2.2.3.8 is: 
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By equating this ∆Hm1 estimation to the Zhang’s one (eq 2.2.3.7), it is possible to determine the 
value of Rs1 related to Tm1: 
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(2.2.3.10) 
Rs1 is determined according to Newton’s method by assuming a relative tolerance of 10–6. Once 
Rs1 is known, ∆Hm1 may be evaluated according to eq 2.2.3.6 or eq 2.2.3.7. By repeating the same 
strategy for further reductions of Tm, the following general equation for Rsi is achieved: 
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Similarly, after finding Rsi, ∆Hmi may be evaluated according to eq 2.2.3.6 or eq 2.2.3.7. In order 
to ensure the reliability of the numerical procedure, ∆T was set equal to 0.1 K. 
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2.3. Solubility and Crystal Size 
It is interesting to evaluate the effect of the variation of melting temperature/enthalpy on a 
nanocrystals property of paramount importance, i.e. the nanocrystals solubility in a solvent 
(typically water when considering drug nanocrystals). The solubility dependence on nanocrystals 
size may be obtained by a classic thermodynamic approach describing the equilibrium between a 
liquid phase (solvent) and a nanocrystalline solid phase (drug) (Prausnitz et al., 1999). By 
assuming that only drug dissolves in the solvent (not vice versa), the equilibrium conditions require 
that the drug fugacity in the solid phase (
∧
s
df ) equals the drug fugacity in the liquid phase (
∧
l
df ): 
∧∧
===
s
d
s
d
l
ddd
l
d γ fffXf                                                                                                                       (2.3.1) 
where γd and Xd are, respectively, the drug activity coefficient and the solubility (molar fraction) 
in the solvent, ldf  is the drug fugacity in the reference state, while sdf  is the drug fugacity in the 
solid state. Accordingly, the drug solubility in the liquid phase reads: 
d
l
d
s
d
d
γ
1
f
fX =                                                                                                                                           (2.3.2) 
By assuming ldf  as the fugacity of the pure drug in the state of undercooled liquid at the system 
temperature (T) and pressure (P), the ratio ldsd ff  is obtainable by: 
( )sdld41 ln ffRTG =∆                                                                                                                           (2.3.3) 
where R is the universal gas constant and 41G∆  represents the variation of the molar Gibbs’ free 
energy between the state of undercooled liquid drug (state 4) and that of solid (nanocrystalline) 
drug (state 1). 41G∆  may be conveniently evaluated according to the thermodynamic cycle 
depicted in Figure 2.5: solid nanocrystals at T and P represent state 1; state 2 portrays nanocrystals 
heated, at constant pressure (P), up to their melting temperature Tm; state 3 depicts the completely 
melted nanocrystals at Tm and P; and, finally, state 4 is achieved by cooling up to T, at constant 
pressure P, the liquid drug (undercooled liquid). Accordingly, it follows: 
( )433221433221414141 SSSTHHHSTHG ∆+∆+∆−∆+∆+∆=∆−∆=∆                                      (2.3.4) 
where ijH∆  and ijS∆  are, respectively, the variation of molar enthalpy and entropy between state 
2-21 
 
j and i. In details: 
 
 
Figure 2.5. Thermodynamic cycle estimating the molar Gibbs’ free energy ( 41G∆ ) variation 
between the state of undercooled liquid drug (state 4) and that of solid (nanocrystalline) drug (state 
1). T is absolute temperature, P is pressure, Tm is nanocrystals melting temperature, while ijH∆  
and ijS∆  are, respectively, the specific enthalpy and entropy variation between state j and i. 
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where sPc  and 
l
Pc  are, respectively, the solid and liquid drug molar specific heat at constant 
pressure, while ∆gm and ∆sm are, respectively, the molar nanocrystals melting Gibbs’ free energy 
and entropy. By rearranging eqs 2.3.3
 
–
 
2.3.10, drug solubility may be expressed as a function of 
determinable parameters: 
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where sl PPP ccc −=∆
 
and ∆hm is the molar melting enthalpy. Finally, it is convenient to remind the 
relation between molar solubility Xd and mass/volume solubility (Cs): 
sol
s
d
d
d
s ρ1 M
M
X
XC
−
=
                                                                                                               (2.3.12) 
where Md and Ms are, respectively, the drug and solvent molecular weight, while ρsol is the solvent 
density. 
For a better understanding of the physical meaning of eq 2.3.11, Figure 2.6 and Figure 2.7 exhibit 
Xd trend in rather artificial but useful situations. In particular, ideal conditions (γd = 1) with two 
different constant values of T (25 and 37°C) and ∆hm (23479 and 33541 J/mol), which are typical 
for small organic drugs, were assumed. Furthermore, Pc∆  was set equal to 103 J/mol°C, another 
typical value for small organic drugs. It appears clear that, no matter the values of T or ∆hm, an 
increase of Tm is reflected in a reduction of Xd, which is reasonable as the higher Tm the more stable 
the crystal is. Accordingly, its dissolution in an external solvent is less favored, which implies the 
reduction of Xd. Moreover, eq 2.3.11 indicates that Xd increases with T (Figure 2.6) and decreases 
with ∆hm (Figure 2.7). While the first occurrence concerns the majority of solid-solvent couples, 
the second one is connected to the thermodynamic stability of the crystalline network. Indeed, a 
higher ∆hm implies a more stable crystalline network whose destruction due to the external solvent 
is less favored. Although real cases are considerably more complicated as the activity coefficient 
γd may depend on Xd and since Tm decrease implies ∆hm simultaneous reduction (amply discussed 
in section 2.2), Figures 2.6 and 2.7 allow capturing the physical essence of eq 2.3.11. 
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Figure 2.6. Ideal (γd = 1) molar solubility (Xd) dependence (eq 2.3.11) on melting temperature 
(Tm) at constant molar melting enthalpy (∆hm) for two different operating temperatures (T) and 
Pc∆ = 103 J/mol°C. 
 
 
 
Figure 2.7. Ideal (γd = 1) molar solubility (Xd) dependence (eq 2.3.11) on melting temperature 
(Tm) at constant operating temperature (T) for two different values of molar melting enthalpy (∆hm) 
and Pc∆  = 103 J/mol°C. 
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2.4. Conclusions 
In this chapter, a thermodynamic mathematical model able to evaluate the simultaneous reduction 
of melting temperature/enthalpy with crystal size was described. One of the main advantages of 
this approach resides in the absence of fitting parameters as all those present may be 
experimentally measured or theoretically determined. In addition, this model is able to take 
account of the shape of crystals, by overcoming the traditional and unrealistic simplification of 
spherical crystals. Finally, its combination with the classic thermodynamic approach describing 
the solid/liquid equilibrium was exposed. Therefore, a clear connection between typical bulk 
thermal properties (Tm and ∆hm) and solutions properties (Xd) was established. 
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CHAPTER 3 
 
MODEL VALIDATION 
 
 
3.1. Materials 
Nimesulide (NIM) is a non-steroidal anti-inflammatory (NSAID) with pain medication and fever-
reducing properties. Its approved indications are the treatment of acute pain, the symptomatic 
treatment of osteoarthritis, and primary dysmenorrhoea in adolescents and adults above 12 years 
old. It has a multifactorial mode of action and is characterized by a fast onset of action. It works 
by blocking the production of prostaglandins (a chemical associated with pain), thereby relieving 
pain and inflammation. NIM is absorbed rapidly following oral administration (Bernareggi, 1998) 
and undergoes extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears 
to be biologically active). Food, gender, and advanced age have negligible effects on NIM 
pharmacokinetics. NIM has a relatively rapid onset of action, with meaningful reductions in pain 
and inflammation observed within 15 minutes from drug intake (Rainsford, 2006; Bianchi and 
Broggini, 2003). The therapeutic effects of NIM are the result of its complex mode of action, which 
targets a number of key mediators of the inflammatory process such as COX-2 mediated 
prostaglandins, free radicals, proteolytic enzymes, and histamine (Rainsford, 2006). Clinical 
evidence is available to support a particularly good profile in terms of gastrointestinal tolerability. 
(Laporte et al., 2004). 
Nifedipine (NIF) is a drug used to manage angina, high blood pressure, Raynaud’s phenomenon, 
and premature labor. It is one of the treatments of choice for Prinzmetal angina. It may be used to 
treat severe high blood pressure during pregnancy. Its use in preterm labor may allow more time 
for steroids to improve baby’s lungs and time to transfer the mother to a well-qualified medical 
facility before delivery. NIF is taken by mouth and comes in fast and slow release formulations. 
NIF is a calcium channel blocker. Although NIF and other dihydropyridines are commonly 
regarded as specific to the L-type calcium channel, they also possess non-specific activity towards 
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other voltage-dependent calcium channels (Curtis et al., 2001; McDonald et al., 1994). NIF has 
additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an 
antimineralocorticoid (Luther, 2014). 
Griseofulvin (GRI) is an antifungal drug used to treat a number of types of dermatophytoses 
(ringworm). This includes fungal infections of the nails and skin when antifungal creams are 
ineffective. It is taken by mouth. GRI works by interfering with fungal mitosis. GRI is used orally 
only for dermatophytosis. It is ineffective topically. It is reserved for cases with nail, hair, or large 
body surface involvement (Tripathi, 2008). The drug binds to tubulin, interfering with microtubule 
function, thus inhibiting mitosis. It binds to keratin in keratin precursor cells and makes them 
resistant to fungal infections. The drug reaches its site of action only when hair or skin is replaced 
by the keratin-GRI complex. GRI then enters the dermatophyte through energy-dependent 
transport processes and binds to fungal microtubules. This alters the processing for mitosis and 
also the underlying information for the deposition of fungal cell walls. 
 
3.1.1. Properties Evaluation 
The melting temperature/enthalpy (Tm/∆Hm) and the difference of specific heat capacity at constant 
pressure between the liquid and solid drug may be measured by a differential scanning calorimeter 
(DSC). After calibrating DSC with indium, the actual measurement on drug or drug-carrier 
mixture consists in placing about 2 mg of sample in a pierced aluminum pan subsequently heated 
at a scanning rate of 10°C per minute under an inert atmosphere of nitrogen. The solid drug density 
may be determined by a helium pycnometer, while the liquid one as the ratio between drug 
molecular weight and its liquid molar volume (Mv) obtained by the group contribution method 
(Fedors, 1974; Van Krevelen and Hoftyzer, 1976) implemented in Breitkreutz’s software 
(Breitkreutz, 1974). 
The determination of the drug solid-vapor surface tension ( svγ
∞
) may be performed according to 
the following equation of state (Kwok and Neumann, 1999): 
( ) 1e
γ
γ2θcos
2svlv
i γγβ
lv
i
sv
i −=
∞
−−∞
                                                                                                (3.1.1.1) 
where θi is the contact angle of the liquid “i” on the solid drug, β is a model fitting parameter, and 
lv
iγ  is the liquid i-vapor surface tension. Equation 3.1.1.1 fitting to the experimental cosθi of 
different liquids yields svγ
∞
 and β. Contact angles may be measured by a tensiometer. The drug 
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liquid-vapor surface tension ( lvγ
∞
) may be evaluated by the parachor method (Van Krevelen, 1990): 
4
v
slvγ 





=
∞ M
P
                                                                                                                         (3.1.1.2) 
while the solid-liquid one ( slγ
∞
) according to Young’s equation for pure substances (θ = 0) 
(Adamson and Gast, 1997): 
lvsvsl γγγ
∞∞∞
−=
                                                                                                                        (3.1.1.3) 
The drug solid-water surface tension ( sl1γ ) may be determined by Young’s equation (Adamson and 
Gast, 1997): 
1
lv
1
svsl
1 θcosγγγ −= ∞                                                                                                              (3.1.1.4) 
The drug Tolman’s length (δ), i.e. 1/3 of the drug molecule diameter (Rowlinson and Windom, 
1982), may be evaluated by knowing Mv and assuming spherical drug molecules: 
3
A
v
π
6
3
1
δ
N
M
=                                                                                                                         (3.1.1.5) 
where NA is Avogadro’s number (Tolman, 1949). 
 
3.2. Molecular Dynamics 
3.2.1. Set-up 
Due to the intrinsic difficulties in obtaining Tm/∆Hm of specific size and shape nanocrystals from 
experimental tests, the present work resorts to molecular dynamics (MD) simulations in order to 
evaluate the aforementioned properties. The atomistic MD simulations explicitly represent the 
atoms constituting a nanocrystal, with the result that Tm/∆Hm evaluations may become 
computationally unfeasible, especially for large crystals. In the present study, reference model 
volumes were selected as the best compromise among the computational time required to 
accurately derive Tm/∆Hm and the values necessary for the comparison with the thermodynamic 
model. The minimum simulated volume in each data set ensures the construction of a reliable 
nanocrystal molecular model, featuring at least three crystallographic units in each direction 
whatever the nanocrystal shape and shape factor are. 
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NIM single crystal structure was retrieved from the Cambridge Structural Database (Cambridge, 
UK) (CCDC 773602) (Groom et al., 2016). NIM orthorhombic Pca21 crystal cell parameters are 
the following: a 16.1268 Å, b 5.0411 Å, c 32.761 Å, α 90°, β 90°, γ 90°. 
The crystal cell was optimized by using Dreiding’s force field with charges derived by fitting the 
electrostatic potential surface of the optimized structure at B3LYP/6-31G (d,p) level by Turbomole 
7.1 (http://www.turbomole-gmbh.com) and RESP method (Bayly et al., 1993; Sanphui et al., 
2011). NIM single crystal nanoparticles (NPs) of appropriate dimensions and shape were built by 
employing the Nanocluster module present in the Materials Studio v. 6.1 (Accelrys Inc., USA) 
program (http://accelrys.com/products/collaborative-science/biovia-materials-studio/). Free 
boundary conditions (free surfaces in a vacuum) were applied to MD simulations, which were 
performed within the canonical ensemble (NVT) where a constant temperature T was maintained 
by using Berendsen’s method in a constant volume V (Berendsen et al., 1984). The van der Waals 
and electrostatic interactions were modeled by using Lennard-Jones’ potential and a group 
contribution method, respectively, truncated at 1.20 nm. A 1 fs time step was used throughout 
simulations. NIM NPs were first relaxed at 300 K for 1 ns before gradually heating them at 
intervals. Then, NPs were equilibrated for at least 15 ns at each temperature assuming the last 
phase space point of a calculation as an input for the next temperature calculation. MD simulations 
were run by the Materials Studio v. 6.1 software in an in-house cluster. 
Nanocrystals Tm was evaluated by calculating the potential energy per NIM molecule during 
heating (at each temperature, potential energy was averaged over the last 5 ns of each simulation 
with at least 500 independent configurations) and determining the melting point as the temperature 
where potential energy changes abruptly at the first-order transition point. In addition, ∆Hm could 
be calculated from the associated increment of potential energy. 
The computational procedure described above was also applied to two further drugs, namely NIF 
and GRI. The unit cell of NIF (CCDC BICCIZ) has the following properties: monoclinic P1, a 
10.923 Å, b 10.326 Å, c 14.814 Å, α 90°, β 92.7°, γ 90°. GRI (CCDC GRISFL02) has a tetragonal 
cell and a P41 space group with lattice parameters: a 8.967 Å, b 8.967 Å, c 19.904 Å, α 90°, β 90°, 
γ 90°. The COMPASS force field (Kumar and Shastri, 2014; Zhu et al., 2012) was applied to these 
MD simulations with charges calculated at B3LYP/6-31G(d) level. 
 
3.2.2. Comparison 
With the aim of validating the trends predicted by the presented thermodynamic model, MD 
calculations were performed in order to derive Tm/∆Hm behavior of parallelepiped-shaped 
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nanocrystals as a function of selected shape factors (ξ = 0.1, 1, 10) for the considered three small 
organic drugs, NIM, NIF, and GRI. 
Figures 3.2.2.1 and 3.2.2.2 display the comparison between NIM Tm/∆Hm reductions with the 
crystal volume (VC) decrease predicted by the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; solid 
lines) and those obtained by MD approach (open symbols). MD calculations confirm the decrease 
of Tm and ∆Hm as a function of nanocrystal volume predicted by the thermodynamic model. 
Moreover, the influence of shape factor (ξ) at constant crystal volume is properly resolved. 
A further verification of the model was performed by considering the two-remaining small organic 
drugs, NIF and GRI, both belonging to Amidon’s class II (low water solubility and good 
permeability). Figures 3.2.2.3 and 3.2.2.4 display the comparison between NIF Tm/∆Hm reductions 
predicted by the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; solid lines) and those obtained by 
MD approach (open symbols). Similarly, Figures 3.2.2.5 and 3.2.2.6 display the comparison 
between GRI Tm/∆Hm reductions predicted by the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; 
solid lines) and those obtained by MD approach (open symbols). Hence, a reasonable agreement 
between the presented model predictions and MD simulations is clearly exhibited also for the 
considered two-other organic drugs, namely NIF and GRI. 
 
 
Figure 3.2.2.1. Nimesulide. Comparison between the melting temperature (Tm) reduction with the 
crystal volume (VC) decrease according to the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; solid 
lines) and the molecular dynamics approach (symbols). The simulations were performed assuming 
nimesulide nanocrystals as parallelepipeds characterized by a square base (β = 1), three different 
shape factors (ξ = 0.1, 1, 10), and a nanocrystals mass fraction Xnc = 1. 
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Figure 3.2.2.2. Nimesulide. Comparison between the melting enthalpy (∆Hm) reduction with the 
crystal volume (VC) decrease according to the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; solid 
lines) and the molecular dynamics approach (symbols). The simulations were performed assuming 
nimesulide nanocrystals as parallelepipeds characterized by a square base (β = 1), three different 
shape factors (ξ = 0.1, 1, 10), and a nanocrystals mass fraction Xnc = 1. 
 
Figure 3.2.2.3. Nifedipine. Comparison between the melting temperature (Tm) reduction with the 
crystal volume (VC) decrease according to the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; solid 
lines) and the molecular dynamics approach (symbols). The simulations were performed assuming 
nifedipine nanocrystals as parallelepipeds characterized by a square base (β = 1), two different 
shape factors (ξ = 1, 10), and a nanocrystals mass fraction Xnc = 1. 
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Figure 3.2.2.4. Nifedipine. Comparison between the melting enthalpy (∆Hm) reduction with the 
crystal volume (VC) decrease according to the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; solid 
lines) and the molecular dynamics approach (symbols). The simulations were performed assuming 
nifedipine nanocrystals as parallelepipeds characterized by a square base (β = 1), two different 
shape factors (ξ = 1, 10), and a nanocrystals mass fraction Xnc = 1. 
 
Figure 3.2.2.5. Griseofulvin. Comparison between the melting temperature (Tm) reduction with 
the crystal volume (VC) decrease according to the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; 
solid lines) and the molecular dynamics approach (symbols). The simulations were performed 
assuming griseofulvin nanocrystals as parallelepipeds characterized by a square base (β = 1), three 
different shape factors (ξ = 0.1, 1, 10), and a nanocrystals mass fraction Xnc = 1. 
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Figure 3.2.2.6. Griseofulvin. Comparison between the melting enthalpy (∆Hm) reduction with the 
crystal volume (VC) decrease according to the thermodynamic model (eqs 2.2.2.6 and 2.2.2.8; solid 
lines) and the molecular dynamics approach (symbols). The simulations were performed assuming 
griseofulvin nanocrystals as parallelepipeds characterized by a square base (β = 1), three different 
shape factors (ξ = 0.1, 1, 10), and a nanocrystals mass fraction Xnc = 1. 
 
3.3. Theoretical Considerations 
Being very difficult to establish the smallest volume of a crystalline solid constituted by small 
organic molecules, obviously, the developed thermodynamic model relies on the hypothesis that 
the crystalline phase has always the same properties regardless of crystal size (aside from the 
surface tension in spherical crystals). Nevertheless, some considerations may be made by resorting 
to the classical nucleation theory according to which the critical nucleation radius (rc) of a spherical 
crystal corresponds to the maximum difference between Gibbs’ energy of the solid and liquid 
phases (∆G): 
2
c
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where ρs represents solid density, ∆Hm∞ and Tm∞ are the melting enthalpy and temperature of the 
infinitely large crystal, while Tc is the undercooling temperature (Tc < Tm∞). In the case of 
parallelepiped-shaped crystals, eq 3.3.3 becomes: 
VG
r
∆






ξ+β+=
∞
sl
c
γ111
3
2
                                                                                                                       (3.3.4) 
where β and ξ are, respectively, the length/width and height/width ratios characterizing the crystal. 
At this point, it is interesting to compare Tc and Tm as a function of crystal volume (VC) according 
to the theory developed by Brun and co-workers for spherical nanocrystals (Brun et al., 1973), the 
starting point of the thermodynamic model proposed in this work: 
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where rC represents nanocrystal radius and ρl is liquid density. It is noticeable that, as ρs and ρl are 
quite similar in value, eq 3.3.5 may be simplified into: 
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which is nothing but the well-known Gibbs-Thomson’s equation. 
 
Figure 3.3.1. Comparison between nimesulide undercooling (Tc; eqs 3.3.3 and 3.3.4) and melting 
(Tm; eqs 3.3.5 and 2.2.2.6) temperatures as a function of crystal volume (VC) for spherical (gray 
and thin lines) and cubic (black and thick lines) crystals. 
 
Figure 3.3.1 demonstrates that, in the case of spherical nanocrystals (gray and thin lines), the two 
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approaches yield very different values of VC when Tc = Tm. Indeed, Tm (continuous gray line; eq 
3.3.5) and Tc (dashed gray line; eq 3.3.3) curves are completely detached from each other. This 
result indicates that Brun’s theory (eq 3.3.5) relying on Gibbs-Duhem’s equations and the 
nucleation approach (eqs 3.3.3 and 3.3.4) produce different outcomes. In particular, it appears that 
Brun’s theory predicts the existence of smaller nanocrystals than those predicted by the nucleation 
approach. Interestingly, in the case of a cube (similar results are also obtainable for different 
shaped parallelepipeds), Tm trend according to the approach of the present work (eq 2.2.2.6; black 
and thick line) is considerably closer to that predicted by the nucleation theory (eq 3.3.4; black and 
dashed thick line). In the light of the approximations adopted to derive eqs 3.3.3 and 3.3.4 (with 
particular reference to the evaluation of ∆GV), it seems that the outcomes of the developed model 
are compatible with those of the nucleation theory. 
In the case of cylindrical crystals, similar considerations could also be made, although the situation 
is complicated by the fact that the lateral surface energy of a cylinder reduces with cylinder radius 
as predicted by Tolman’s equation (eq 2.2.1.3). Accordingly, an ad hoc mathematical approach 
should be necessary. 
The experimental verification (from the thermal and solubility point of view) of the presented 
model is very complicated. Indeed, not only the experimental determination of nanocrystals 
solubility is affected by several issues, as previously stated in Section 1.5, but also the 
simultaneous experimental determination of nanocrystals melting temperature/enthalpy and size 
is very complex. In the case of metals, although some uncertainties still exist (Goswani and Nanda, 
2012), the thermodynamic models validation is achievable by means of a variety of techniques 
such as DSC for melting temperature/enthalpy and Transmission Electron Microscopy (TEM) for 
crystals size. Conversely, in the case of drug nanocrystals, almost all the authors exploring the 
melting point depression of organic drugs considered drug crystals embedded in regular inorganic 
or organic nanoporous matrices (Hamilton et al., 2012). Consequently, the melting 
temperature/enthalpy depression could be evaluated, for instance, by means of DSC, while 
nanocrystals size could be related to pores size. However, this is insufficient for the complete 
solution of the problem, as nicely documented in Sonnemberger et al., 2016. The authors realized 
that an amorphous drug layer develops between pore wall and nanocrystal surface due to drug-
wall interactions. Accordingly, the determination of crystals size may be performed only 
indirectly. Indeed, it is the same situation arising when water freezes inside inorganic materials 
such as silica (Ishikiriyama et al., 1995). Since, in this last case, the determination of the 
amorphous layer thickness is feasible by following Ishikiriyama’s procedure, it was decided, in 
the present study, to adapt the developed model in order to evaluate the silica pores size distribution 
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by relying on DSC measurements. The comparison between the pores size distribution according 
to the model and BET (Brunauer, Emmett, and Teller) measurements is displayed in Figure 3.3.2. 
The agreement between the two approaches is substantially acceptable and seems to prove the 
reliability of the developed model. 
Despite this encouraging result, an analogous validation for the ensemble of polydispersed 
nanocrystals in a polymeric matrix constituted by crosslinked microparticles (Colombo et al., 
2009) proves complicated. While melting temperature may be easily determined by DSC, crystals 
size may be only deduced by resorting, for instance, to a mathematical interpretation of X-ray 
diffraction patterns (Bergese et al., 2004). Accordingly, more than an experimental validation of 
the model, this could resemble a comparison between two different models. Ultimately, all the 
previous considerations suggested MD simulations as the most reliable (and feasible) approach to 
validating the presented thermodynamic model. 
 
 
Figure 3.3.2. Comparison between the silica pores size distribution according to the presented 
model (dashed line) and BET measurements (solid line). 
 
3.4. Solubility Evaluation 
While atomistic MD simulations represent a very useful tool for validating the proposed 
thermodynamic model from the prediction of melting temperature/enthalpy point of view, a rather 
more complex problem is the model validation when it predicts the solubility increase with the 
decrease of nanocrystals dimension. Indeed, as mentioned in Chapter 1, the experimental work on 
nanocrystals is rendered problematic by several issues such as a) the manufacturing processes 
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which usually alter nanocrystals characteristics by introducing lattice defects, b) the presence of 
little impurities able to affect solubility, and c) the well-known Ostwald ripening (Madras et al., 
2003) which affects the polydispersed nanocrystals ensemble. In particular, the last phenomenon 
results in the growth of larger and hence less soluble crystals at the expense of the smaller and thus 
more soluble ones. This, in turn, is reflected in the asymptotic decrease of experimental solubility. 
Unfortunately, a further problem afflicts the experimental verification of this model from the 
solubility point of view again. As discussed in Chapter 2 (see eq 2.3.11), not only the knowledge 
of the drug activity coefficient (γd) in the liquid phase is essential but also its dependence on 
solubility (or crystal dimension) is necessary for a reliable comparison between experimental 
solubility and model predictions. In the light of all these difficulties, it was decided, in this study, 
to abandon the idea of validating experimentally the model from the solubility point of view in 
favor of the evaluation of γd by resorting to experimentally known solubility data. For this purpose, 
the interpretation of experimental data obtained from intrinsic dissolution rate (IDR) tests proved 
to be very useful. This test aims to evaluate the solid dissolution rate in a solvent (water) at a fixed 
temperature and under carefully controlled hydrodynamic conditions.  
 
3.4.1. Intrinsic Dissolution Rate 
IDR is the typical test employed in the pharmaceutical field to evaluate solid drugs dissolution and 
performed by different experimental set-ups. One of the most famous consists in a drug disk fixed 
on a rotating shaft (ω is angular velocity) and immersed in a dissolving medium (typically water 
or an aqueous solvent) of very large volume. In order to greatly simplify the theoretical analysis, 
the drug cylinder lateral surface is coated by an impermeable membrane against the dissolving 
medium so that dissolution occurs only at the disk bottom plane surface. According to Levich 
(Levich, 1962), the first to model the test, the solid and liquid phases perfectly adhere (no fluid 
slippage). Therefore, at the liquid-solid interface, the dissolving fluid moves exclusively in a 
rotational manner. Immediately after the interface, the axial (vy), tangential (vθ), and radial (vr) 
fluid velocity components are all different from zero, the reason for which the fluid approaches 
the solid surface according to a spiral trajectory. Away from the disk rotating surface, vθ and vr 
reduce progressively. Owing to the fluid continuity and the perfect adhesion to the solid surface, 
the rotating disk attracts the fluid from the bottom and moves it radially, thus causing the fluid 
streamlines to describe a loop. By solving the momentum and continuity equations, Levich 
concluded that the only important velocity component is vy when the distance from the rotating 
surface is longer than a threshold value, the hydrodynamic boundary layer (δ0). In addition, he 
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demonstrated that solids dissolution is ruled by the diffusive transport across the so-called 
diffusive boundary layer (δ < δ0) whose thickness depends on the fluid kinematic viscosity, angular 
velocity, and the solid diffusion coefficient in the solvent. 
Levich’s theoretical analysis allows schematizing the dissolution process, which may be 
considered a consecutive steps process driven by energy changes (Grassi et al., 2007). The first 
step consists in the contact of the solvent with the solid surface (wetting), which leads to the 
creation of a solid-liquid interface by starting from a solid-vapor one. The cleavage of the 
molecular bonds of the solid (melting) and the molecules movement toward the solid-liquid 
interface (solvation) are the second and third steps, respectively. The final step is the transfer of 
the solvated molecules from the interfacial region to the bulk solution (diffusion). Obviously, each 
stage of the process requires energy to occur and the total energy for dissolution is the sum of the 
contributions related to the four aforementioned steps. Generally, the most important contribution 
to solids dissolution in terms of energy is represented by the melting step. While solvation and 
diffusion depend on the solid-solvent couple chemical nature and the dissolution environment 
conditions (temperature and mechanical agitation, for example), wetting and melting are also 
affected by the solid microstructure. 
According to Levich, while the concentration of solid molecules at the solid surface is assumed 
equal to the solid solubility (Cs) in the dissolving medium, the drug concentration in the bulk 
solution (Cb) is presumed homogeneous and lower than Cs due to the mass transfer resistance 
offered by the boundary layer. By applying Fick’s second law of diffusion to the boundary layer 
and assuming a linear solid concentration within it, the temporal increase in Cb is obtained by: 
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where t is time, V is the dissolving medium volume, S is the solid surface area available for 
dissolution, and kd is the intrinsic dissolution constant, i.e. the ratio between the solid diffusion 
coefficient (Dd0) in the solvent and δ. By assuming that Cb is initially zero, eq 3.4.1.1 solution 
leads to: 
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A possible way to consider the effect of poor wettability on solids dissolution consists in 
considering the presence of a mass transfer resistance (1/km) at the solid-liquid interface in such a 
way that Fick’s second equation must be solved by applying the following boundary conditions: 
3-14 
 
solid/liquid interface 
( )0sm
0
d0 =
=
−−=
∂
∂
X
X
CCk
X
CD
                                                                                               (3.4.1.3) 
boundary layer/dissolving medium bulk 
t
C
kS
V
t
C
DS
V
X
C
X d
d
δd
d b
d
b
d0δ
−=−=
∂
∂
=
          
δb == XCC                                                        (3.4.1.4) 
Equation 3.4.1.3 states that the solid concentration at the solid-liquid interface is variable because 
it increases from zero (the initial condition in the boundary layer) to Cs, with km ruling this kinetic 
process. Accordingly, high km values translate into a rapid interfacial drug concentration increase 
and a good solid wettability, while low km values are responsible for a slow interfacial drug 
concentration rise and a poor solid wettability. Therefore, infinitely high km values imply the 
absence of wettability problems of the solid surface for the solvent. In the light of eqs 3.4.1.3 – 
3.4.1.4, Fick’s second law (for a linear concentration profile in the boundary layer) leads to: 
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Thus far, solids properties such as Cs have been implicitly assumed constant during dissolution. 
However, it is well-known that many organic compounds may exist in different crystalline 
structures such as polymorphs and solvates, as it often happens to organic drugs (Nogami et al., 
1969). Moreover, temperature, pressure, and surrounding conditions (i.e. the existence of a liquid 
phase in contact with the solid phase) determine which crystalline structure is the most stable. 
Accordingly, during dissolution (at constant temperature and pressure), the contact with a new 
fluid phase (solvent) may induce a solid phase transformation from a polymorphic phase (the most 
stable configuration in the absence of dissolving medium) to another (the most stable configuration 
in the presence of dissolving medium). Hence, the polymorphic transformation may take place in 
some solvents but not in others. As, for thermodynamic reasons, a solid exhibiting polymorphism 
should possess different activities depending on its structure (Higuchi et al., 1967), the 
polymorphic transformations generally imply a variation of Cs, thus highly influencing the entire 
dissolution process. A particularly interesting phase transformation is that of an amorphous 
compound which becomes a solid when encounters an aqueous dissolving medium. In this case, a 
considerable variation (decrease) of drug solubility may also occur (Nogami et al., 1969). By 
assuming that the release rate at the amorphous compound/dissolving medium interface is much 
faster than the mass transport process across the diffusion layer, superficial phase transformations 
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occur until the entire dissolving surface becomes a crystalline solid. This indicates that solubility 
ranges from an initial value (Csi), that of the amorphous state, to a final one (Csf), that of the 
crystalline solid. By supposing that the rate of crystal growth is 1) proportional to the degree of 
supersaturation and 2) ruled by a first order kinetics with respect to concentration, the solubility 
variation may be described by the following equation (Nogami et al., 1969): 
( )ssfrsd
d CCk
t
C
−=                                                                                                                 (3.4.1.6) 
where Cs is the time-dependent solid solubility and kr is the recrystallization constant. Equation 
3.4.1.6 solution leads to: 
( ) tkCCCC resfsisfs −−+=                                                                                                       (3.4.1.7) 
Furthermore, by assuming that the phase transformation leaves the dissolving surface unvaried and 
Dd0 in the diffusion layer is the same for the two forms (amorphous and crystalline), the entire 
dissolution process may be described by introducing eq 3.4.1.7 into eq 3.4.1.1: 
( )[ ]bsfsisfdb redd CCCCkVStC tk −−+= −                                                                                   (3.4.1.8) 
whose solution is: 
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In the case of sink conditions (Cbmax < 0.2Csf, i.e. Cs(t) – Cb ≈ Cs(t) in eq 3.4.1.8), eq 3.4.1.9 is 
simplified in:  
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By starting from eq 3.4.1.10, it is possible to find a simple way to evaluate kd and Csi: 
sf
db
d
d C
V
Sk
t
C
t
=
∞→
                                                                                                              (3.4.1.11) 
si
d
0
b
d
d C
V
Sk
t
C
t
=
=
                                                                                                                (3.4.1.12) 
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As 
→∞tt
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d b
 and 
0
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=tt
C
 may be numerically evaluated from experimental data and Csf is 
experimentally known, eqs 3.4.1.11 and 3.4.1.12 allow the evaluation of kd and Csi. Then, eq 
3.4.1.10 fitting to experimental data allows the determination of the last fitting parameter, i.e. kr. 
In this way, it is possible to overcome the issue connected with the correlation of an elevated 
number of parameters in both eqs 3.4.1.9 and 3.4.1.10. 
While all the above considerations regard the dissolution of a pure solid phase, it may be very 
important to consider the dissolution of a uniform, intimate, and non-disintegrating mixture of two 
solid compounds, A and B. A particularly interesting case is that of A and B representing, 
respectively, the crystalline and amorphous phases of the same compound. In this situation, the 
global dissolution rate depends on 1) the crystalline and amorphous solubility and 2) the compound 
diffusion coefficient in the boundary layer facing the mixture surface. As dissolution proceeds, 
however, the amorphous phase content of the solid-liquid interface reduces due to its higher 
solubility, while the crystalline fraction of the interface increases up to the total disappearance of 
the amorphous phase. In other words, as the speed of the receding front for the amorphous phase 
is higher than that relative to the crystalline phase during dissolution, the position of the amorphous 
phase front (La) is farther from the initial interface than that of the crystalline phase (Lc). Obviously, 
the higher the difference (La – Lc), the lower the amorphous phase dissolution rate, as the molecules 
detaching from the amorphous phase travel an increasing distance represented by the sum of (La – 
Lc) and δ. Hence, the following set of equations holds (Grassi et al., 2007): 
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where Sa and Sc are, respectively, the dissolving surfaces of the amorphous and crystalline phases 
(S = Sa + Sc), kdc and kda are, respectively, the crystalline and amorphous phases dissolution 
constants (theoretically equal), while Csc and Csa are, respectively, the crystalline and amorphous 
drug solubility. Furthermore, Csa time dependency is represented by eq 3.4.1.7. While Mc indicates 
the mass of the crystalline phase, Aa and Ac represent, respectively, the amount of the amorphous 
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and crystalline phases per unit volume and are defined by: 
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where ρa and ρc are, respectively, the amorphous and crystalline phases density, while Xc is the 
crystalline mass fraction in the mixture. Sa and Sc are evaluated by assuming that the amorphous 
and crystalline phases consist of small cubes of side ∆X. Thus, the number of the amorphous (Na) 
and crystalline (Nc) cubes is represented by Va/∆X3 and Vc/∆X3, respectively, where Va and Vc 
indicate, respectively, the volume occupied by the amorphous and crystalline phases in the 
assumed non-porous mixture. By assuming that the dissolving surface, for each phase, is the sum 
of the six cubes faces (the same final result may be also obtained by considering only the face 
perpendicular to the dissolution direction), it follows that Sa = 6∆X2Na and Sc = 6∆X2Nc. The 
substitution of the expressions of Na and Nc leads to Sa = 6Va/∆X and Sc = 6Vc/∆X. As Va/Vc = 
(ρc/ρa)(1 – Xc)/Xc, then Sa/Sc = (ρc/ρa)(1 – Xc)/Xc. Hence, it may be concluded that: 
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It is easy to verify that when ρa = ρc, Sa = SAa/(Aa + Ac) and Sc = SAc/(Aa + Ac). 
Fundamentally, eq 3.4.1.13 states that the variation of the compound concentration in the 
dissolving medium is due to the sum of two distinct contributions: the one of the crystalline phase 
(eq 3.4.1.13 first right-hand side term) and that of the amorphous phase (eq 3.4.1.13 second right-
hand side term). In particular, while the mass transport resistance for the crystalline phase is 
represented by 1/kdc, this phase being always in direct contact with the dissolving medium, the 
mass transport resistance relative to the amorphous phase is represented by τ(La – Lc)/(Dd0 ε). 
Indeed, before reaching the boundary layer (the mass transport resistance equals 1/kda), the 
compound molecules detaching from the amorphous phase travel the additional length (La – Lc). 
In order to consider the path tortuosity (τ) and porosity (ε), this length is multiplied by τ/ε. During 
the amorphous phase dissolution, the mixture becomes porous and its porosity is: 
a
a
ρ
ε
A
=
                                                                                                                                (3.4.1.19) 
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While eq 3.4.1.14 expresses the reduction of the crystalline mass and, consequently, allows 
evaluating Lc increase with time, eq 3.4.1.15 is a mass balance stating that the compound amount 
dissolved up to time t equals the one present in the dissolving medium (VCb). This last equation 
allows the determination of the time variation of La. 
The described model is suited to studying the interesting practical situation arising when the 
crystalline phase consists entirely of nanocrystals. 
 
3.4.2. Case Study: Griseofulvin 
The theoretical considerations presented in the previous section (Section 3.4.1) allow establishing 
the dependence of γd on solubility and, thus, nanocrystals radius. Notably, this information is 
essential for a realistic prediction of the solubility increase with the reduction of nanocrystals 
dimension, as discussed in Chapter 2 (see eq 2.3.11). In the present case study, the attention is 
focused on GRI (C17H17ClO6), a drug belonging to Amidon’s class II (low water solubility and 
good permeability) whose physical properties are displayed in Table 3.4.2.1. It is an orally 
administered 3. 
Table 3.4.2.1. Griseofulvin physicochemical properties. UCS indicates the diameter of the unit 
cell imagined as a sphere, Mw is molecular weight, slγ
∞
, 
lvγ
∞
, and svγ
∞
 are, respectively, the solid-
liquid, liquid-vapor, and solid-vapor surface energy referring to a plane surface (infinite curvature 
radius), δ0 is Tolman’s length, ρs and ρl are, respectively, the solid and liquid density, Tm∞ and 
∆Hm∞ are, respectively, the melting temperature and enthalpy of the infinitely large crystal, ∆CP 
is the difference between the liquid and solid specific heat at constant pressure, Vm is molar 
volume, while Cs is the solubility in water (37°C). 
Formula C17H17ClO6 Ref 
UCS(nm) 1.45 Puttaraja et al., 1982 
Mw(-) 352.77 - 
slγ
∞
(J/m2) 0.0097  
 
 
 
 
Bergese et al., 2004 
lvγ
∞
(J/m2) 0.0525 
svγ
∞
(J/m2) 0.0622 
ρs(kg/m3) 1494.7 
ρl(kg/m3) 1383.1 
Tm∞(°C) 220.9 
∆Hm∞(J/kg) 124400 
∆CP(J/kg°C) 511 
Vm(m3/mole) 255 . 10–6 
Cs(µg/cm3) - 37°C 11.9 ± 0.5 Grassi et al., 2007 
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Table 3.4.2.2. Estimation of the activity coefficient in water (γd) for different drugs in their 
macrocrystalline state. Xd and Cs represent, respectively, the molar and mass/volume drug 
solubility, while T is temperature.   
Drug Cs(µg/cm3) Xd(-) T(°C) γd(-) Source 
nimesulide 11.8 5.285 . 10–7 37 88148 Table 4.1.1 
griseofulvin 11.9 6.111 . 10–7 37 45832 Table 3.4.2.1 
nifedipine 20.0 1.046 . 10–6 37 53339 Table 3.4.2.3 
paracetamol 17314.0 2.066 . 10–3 30 43 Table 3.4.2.4 
 
Table 3.4.2.3. Nifedipine physicochemical properties. UCS indicates the diameter of the unit cell 
imagined as a sphere, Mw is molecular weight, slγ
∞
, 
lvγ
∞
, and svγ
∞
 are, respectively, the solid-liquid, 
liquid-vapor, and solid-vapor surface energy referring to a plane surface (infinite curvature radius), 
δ0 is Tolman’s length, ρs and ρl are, respectively, the solid and liquid density, Tm∞ and ∆Hm∞ are, 
respectively, the melting temperature and enthalpy of the infinitely large crystal, ∆CP is the 
difference between the liquid and solid specific heat at constant pressure, Vm is molar volume, 
while Cs is the solubility in water (37°C). 
Formula C17H18N2O6 Ref 
UCS(nm) 1.47 Triggle et al., 1980 
Mw(-) 346.34 - 
slγ
∞
(J/m2) 0.0064  
 
 
 
 
Bergese et al., 2004 
lvγ
∞
(J/m2) 0.0461 
svγ
∞
(J/m2) 0.0525 
ρs(kg/m3) 1375.5 
ρl(kg/m3) 1272.3 
Tm∞(°C) 172.8 
∆Hm∞(J/kg) 107500 
∆CP(J/kg°C) 486 
Vm(m3/mole) 272 . 10–6 
Cs(µg/cm3) - 37°C 20 Hecq et al., 2005 
 
administered antimycotic employed to treat several forms of dermatophytosis, including fungal 
infections of nails and skin when antifungal creams are ineffective. 
The first step consists in evaluating γd for GRI in its macrocrystalline state. On the basis of the 
physical properties displayed in Table 3.4.2.1, eq 2.3.11 allows concluding that γd = 45832. This 
extremely high value reveals that the actual solubility of GRI in water at 37°C is far lower than its 
ideal value obtained from eq 2.3.11 for γd = 1. For this purpose, Table 3.4.2.2 shows γd estimation 
for some poorly water-soluble drugs and paracetamol (C8H9NO2), an analgesic and antipyretic 
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without particular solubility problems. It is evident that paracetamol γd is approximately 2-3 orders 
of magnitude lower than that of poorly water-soluble drugs such as NIF (C17H18N2O6), an 
antihypertensive belonging to the class of calcium antagonists and the chemical class of 1,4-
dihydropyridines, and NIM (C13H12N2O5S), a non-steroidal anti-inflammatory (NSAID) with 
analgesic and antipyretic properties. High values of γd are related to a low solubility in a solvent 
and indicate that the solvent environment is uncomfortable for the drug molecule. On the contrary, 
low values of γd are related to a high solubility in a solvent and indicate a situation approaching 
ideality, in which the entropy effects become gradually less important in the solution (Granberg 
and Rasmuson, 1999).  
 
Table 3.4.2.4. Paracetamol physicochemical properties. Mw is molecular weight, Tm∞ and ∆Hm∞ 
are, respectively, the melting temperature and enthalpy of the infinitely large crystal, ∆CP is the 
difference between the liquid and solid specific heat at constant pressure, while Cs is the solubility 
in water (30°C). 
Formula C8H9NO2 Ref 
Mw(-) 151.16  
 
Granberg et al., 1999 
Tm∞(°C) 170.4 
∆Hm∞(J/kg) 179276.7 
∆CP(J/kg°C) 660 
Cs(µg/cm3) - 30°C 17314 
 
The second and third steps to determine γd dependence on solubility consist in evaluating 
nanocrystals dimension and solubility. For this purpose, a mixture of crystalline and amorphous 
GRI was characterized by DSC (Grassi et al., 2007). Briefly, DSC was performed by means of a 
power compensated Pyris 1 DSC by Perkin Elmer. The sample was placed in an aluminum pan 
(about 1.8 mg) and then scanned under an N2 stream of 20 cm3/min at a heating rate of 10°C/min. 
Temperature calibration was performed by employing Hg and In as standards. The obtained DSC 
trace is displayed in Figure 3.4.2.1. It is interesting to observe that, as the endothermic melting 
peak is around 218.7°C, i.e. below the melting temperature of macrocrystalline GRI (220.9°C), 
the presence of GRI macrocrystals may be excluded and the crystalline fraction consists of 
nanocrystals. In order to obtain the nanocrystals size distribution by processing the data depicted 
in Figure 3.4.2.1 according to the approach discussed in Chapter 4 (Section 4.2), it is necessary to 
determine the shape of GRI nanocrystals. For this purpose, the WinXMorph program (Kaminsky, 
2007) suggests that, although the shape of GRI crystal is complicated (see Figure 3.4.2.2), the 
choice of a cubic shape is sufficiently close to the actual one. On the basis of this assumption, the 
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model provides a nanocrystals mass fraction of 0.795, while the amorphous one is 0.205, and the 
crystals size distribution displayed in Figure 3.4.2.3. Figure 3.4.2.3 clarifies that the distribution 
peak is around Rsphere = 11 nm, equivalent to a cube with a side of 17.75 nm (volume of 5596 nm3). 
Although other criteria could be applied, it was decided, in this study, to assume the distribution 
peak radius as the mean dimension of GRI nanocrystals.  
 
 
Figure 3.4.2.1. DSC trace referring to a mixture of nanocrystalline and amorphous griseofulvin. 
T is temperature and Q° indicates the thermal power provided by the instrument. 
 
Figure 3.4.2.2. WinXMorph prediction of griseofulvin crystal shape. 
 
Nanocrystals solubility is then determined by means of the approach described in Section 3.4.1. 
For this purpose, it is, first, necessary to evaluate the characteristics of amorphous GRI, i.e. Csi, kr, 
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and kd by fitting eq 3.4.1.10 to the experimental data shown in Figure 3.4.2.4. In order to overcome 
the issue connected with the correlation of an elevated number of parameters in eq 3.4.1.10, Csi 
and according to the strategy illustrated 
 
Figure 3.4.2.3. Griseofulvin nanocrystals size distribution referring to the data in Figure 3.4.2.1 
opportunely processed according to the approach presented in Chapter 4, Section 4.2. f is frequency 
and Rsphere is the radius of the sphere having the same volume of the cubic nanocrystal. 
 
 
Figure 3.4.2.4. Equation 3.4.1.10 best fit (solid line) to the experimental IDR data (symbols) 
referring to amorphous griseofulvin (T = 37°C; V = 250 cm3; S = 3.14 cm2). The vertical bars 
indicate the standard deviations (data from Grassi et al., 2007). 
 
and kd are evaluated according to the strategy illustrated immediately after the introduction of eq 
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3.4.1.10, thus obtaining kd = 3.41 . 10–5 m/s and Csi = 0.250 kg/m3. This last value, in particular, 
appears to agree with Murdande’s theoretical prediction (Murdande et al., 2010). Hence, for Csi = 
0.250 kg/m3, kd = 4.33 . 10–5 m/s (very close to the initial guess 3.41 . 10–5 m/s), kr = 8.0 . 10–3 s–1, 
and Csf = 0.022 kg/m3 as fitting parameters, eq 3.4.1.10 provides a good fit (see Figure 3.4.2.4).  
The fact that the estimation of Csf is higher than the actual macrocrystalline solubility (0.0119 
kg/m3) is scarcely surprising since a much longer dissolution time should have been considered. 
Nevertheless 
 
Figure 3.4.2.5. Equations 3.4.1.13 – 3.4.1.15  best fit (solid line) to the experimental IDR data 
(symbols) referring to a nanocrystalline/amorphous griseofulvin mixture (T = 37°C; V = 250 cm3; 
S = 3.14 cm2). The vertical bars indicate the standard deviations (data from Grassi et al., 2007). 
 
Nevertheless, this would have meant exceeding the sink conditions, the range in which the 
determination of both kd and kr is much more reliable. On the basis of these results, it was possible 
to fit eqs 3.4.1.13 – 3.4.1.15 to the experimental data referring to a nanocrystalline/amorphous 
mixture and displayed in Figure 3.4.2.5. In order to reduce the number of fitting parameters, the 
physical quantity τ/Dd0 (see eq 3.4.1.13) was set equal to 109 s/m2 since τ ranges from 1 to 3 and 
Dd0, for small organic drugs such as GRI, is approximately 10–9 m2/s in water at 37°C (Grassi et 
al., 2007). Csf (0.25 kg/m3), Csi (0.022 kg/m3), kd (4.3 . 10–5 m/s), and Xnc (0.795) were chosen 
according to what previously found, while Csc and kr were considered the only fitting parameters. 
As shown in Figure 3.4.2.5, a good fit is obtained with Csc = 0.05 kg/m3 and kr = 6.4 . 10–4 s–1. kr 
difference from the amorphous drug one obtained by IDR would allow supposing that this 
parameter may be also affected by the external environment/concentration. However, this last data 
fitting allows determining the solubility of cubic nanocrystals whose average volume is 5596 nm3, 
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equivalent to Rsphere = 11 nm. This is a very important information as it allows establishing a 
relation between nanocrystals dimension and solubility. The knowledge of nanocrystals solubility 
and dimension allows the evaluation of γd as the developed thermodynamic model (see Chapter 2) 
concludes that Tm = 217.4°C and ∆Hm = 121393 J/kg, while ∆CP = 511 J/kg°C. Thus, eq 2.3.11 
yields γd = 12678 for GRI nanocrystals. As this value is lower than the one of GRI macrocrystals 
(45832), nanocrystals solubility is closer to the ideal one than macrocrystals solubility. Finally, it 
is possible to evaluate γd for the smallest (theoretical) nanocrystal, i.e. that characterized by the 
same characterized by the same volume 
 
Figure 3.4.2.6. Activity coefficient (γd) dependence on nanocrystal dimension represented by the 
radius of the sphere (Rsphere) having the same volume of the nanocrystal. The solid line indicates 
the trend of eq 3.4.1.20, while the dots represent the experimental data. 
 
same volume of GRI primitive cell (1.6 nm3; Rsphere = 0.726 nm). Indeed, the developed 
thermodynamic model predicts Tm = 162.3°C and ∆Hm = 75719 J/kg, while ∆CP = 511 J/kg°C. In 
addition, by associating the solubility of amorphous GRI (0.25 kg/m3) with its primitive cell (a 
vanishingly small nanocrystal), eq 2.3.11 yields γd = 16054. Figure 3.4.2.6, by summarizing all 
these findings referring to γd evaluation, helps to clarify that γd substantially decreases with crystal 
dimension (Rsphere) and this trend may be approximated by the following exponential function: 
( )726.0002917.0
d
spheree 16054γ −= R
                                                                                                 (3.4.2.1) 
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The substitution of this expression in eq 2.3.11 provides the actual tendency of solubility to 
increase with Rsphere. In particular, Figure 3.4.2.7 displays the comparison between the ideal and 
actual increments of the ratio Cs/Cs∞ as a function of crystal dimension (Rsphere). As γd reduces with 
crystal size, the actual increment of Cs/Cs∞ exceeds the ideal one, in which γd is constantly equal 
to one.  
 
 
Figure 3.4.2.7. Ideal and actual relative increase in griseofulvin solubility (C) as a function of 
nanocrystal size represented by the radius of the sphere (Rsphere) having the same volume of the 
nanocrystal. Cs∞ is the solubility of an infinitely large nanocrystal (i.e. a macrocrystal). 
 
3.4.3. Case Study: Vinpocetine 
Vinpocetine (VIN, C22H26N2O2) is a semisynthetic derivative of Vinca minor L. alkaloid 
vincamine employed to treat cognitive disorders and related symptoms such as cerebral infarction, 
cerebral hemorrhage residual effects, and cerebral arteries cirrhosis effects (Csanda et al., 1988; 
Lorincz et al., 1976). This basic drug (pKa = 7.1) (Weinshaar and Bristol, 1990) was taken into 
consideration because it is practically insoluble in water (1.6 µg/cm3 at pH = 7.4 and 37°C) (Hasa 
et al., 2011). Its physicochemical properties are displayed in Table 3.4.3.1. VIN physical properties 
when combined with eq 2.3.11 yield γd = 911460, an extremely high value witnessing the very 
scarce affinity of VIN for water. Interestingly, this value is approximately one order of magnitude 
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higher 
higher than those referring to NIM, NIF, and GRI, while it is four orders of magnitude greater than  
 
Table 3.4.3.1. Vinpocetine physicochemical properties. UCS indicates the diameter of the unit cell 
imagined as a sphere, Mw is molecular weight, slγ
∞
, 
lvγ
∞
, and svγ
∞
 are, respectively, the solid-liquid, 
liquid-vapor, and solid-vapor surface energy referring to a plane surface (infinite curvature radius), 
δ0 is Tolman’s length, ρs and ρl are, respectively, the solid and liquid density, Tm∞ and ∆Hm∞ are, 
respectively, the melting temperature and enthalpy of the infinitely large crystal, ∆CP is the 
difference between the liquid and solid specific heat at constant pressure, Vm is molar volume, 
while Cs is the solubility in water (37°C). 
Formula C17H18N2O6 Ref 
UCS(nm) 1.2  
 
 
 
 
 
Hasa et al., 2011 
 
Mw(-) 350.45 
slγ
∞
(J/m2) 0.0072 
lvγ
∞
(J/m2) 0.0312 
svγ
∞
(J/m2) 0.0384 
ρs(kg/m3) 1268 
ρl(kg/m3) 1217 
Tm∞(°C) 149.6 
∆Hm∞(J/kg) 94600 
∆CP(J/kg°C) 374 
Vm(m3/mole) 287 . 10–6 
Cs(µg/cm3) - 37°C, pH 7.4 1.6 
 
that of paracetamol (see Table 3.4.2.4). As in the case of GRI, the evaluation of γd for VIN unit 
cell (the smallest VIN crystal) may be conducted by resorting to eq 2.3.11 and assuming that its 
solubility is 22 µg/cm3, i.e. the one of amorphous VIN (Hasa et al., 2011), Tm = 37°C and ∆Hm =  
26174 J/kg according to the developed thermodynamic model (see Chapter 2 and Figure 3.4.3.1), 
while ∆CP = 374 J/kg°C. This approach leads to γd = 879223. In this case, unlike GRI, a very small 
variation of γd results from considering macrocrystalline VIN. Thus, a simple γd linear dependence 
on Rsphere may be assumed. By embodying this law in eq 2.3.11, the actual trend of C/Cs∞ as a 
function of Rsphere is obtained, as depicted in Figure 3.4.3.2. It may be noticed that the actual 
behavior substantially follows the ideal one. 
VIN case study represents a possible general strategy to evaluate γd(Rsphere) for a generic drug 
provided that its amorphous/macrocrystalline solubility and thermodynamic properties are known, 
for instance, those displayed in Table 3.4.3.1. 
3-27 
 
 
 
Figure 3.4.3.1. Vinpocetine. Reduction of the melting temperature (Tm) and enthalpy (∆Hm) as a 
function of crystal dimension represented by the radius of the sphere (Rsphere) having the same 
volume of the crystal. The shape of vinpocetine crystals is assumed cubic. 
 
 
Figure 3.4.3.2. Ideal and actual relative increase in vinpocetine solubility (C) as a function of 
nanocrystal size represented by the radius of the sphere (Rsphere) having the same volume of the 
nanocrystal. Cs∞ is the solubility of an infinitely large nanocrystal (i.e. a macrocrystal). 
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3.5. Conclusions 
This chapter provides a way to validate the thermodynamic model proposed in Chapter 2 by 
resorting to a molecular dynamics approach (Section 3.2) and other theoretical considerations 
based on the comparison with a previous model (Gibbs-Thomson’s equation) and the nucleation 
theory (Section 3.3). By considering three drugs of class II (poorly soluble and permeable drugs – 
nimesulide, nifedipine, and griseofulvin), the molecular dynamics approach substantially confirms 
the prediction of the thermodynamic model concerning the melting temperature and enthalpy 
reduction with crystals size. In addition, in the light of the nucleation theory, the output of the 
presented thermodynamic model appears much more reasonable than that of a previous well-
known approach (Gibbs-Thomson’s equation). 
The final part of this chapter (Section 3.4) provides an attempt to exploit the thermodynamic model 
to evaluate the dependence of the drug activity coefficient in a solution on drug nanocrystals 
dimension. Indeed, only by knowing this property, it is possible to predict the actual increase in 
solubility when nanocrystals size decrease. It appears to be the first attempt to predict the solubility 
increase by also considering the non-ideal solution properties. 
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CHAPTER 4 
 
MODEL OUTCOMES 
 
 
4.1 Theoretical Results 
To perform a sound comparison among the thermal properties of differently shaped crystals, it is 
no longer possible to refer to sphere radius (Rs), parallelepiped base side (as), and cylinder base 
radius (Rs). Indeed, in doing so, the melting temperature (Tm) and enthalpy (∆Hm) of crystals 
having different volumes and, thus, different masses would be compared. As melting is a bulk 
phenomenon (although it starts from surface), the comparison of the thermal properties should be 
referred to nanocrystals characterized by equal volume VC (sphere 4piRs3/3; parallelepiped asbscs; 
cylinder piRs2Ls) and, consequently, different Rs and as. Accordingly, eqs 2.2.1.8 – 2.2.1.9, 2.2.2.6 
–
 
2.2.2.7, and 2.2.3.6
 
–
 
2.2.3.7 were solved as functions of Rs (sphere), as (parallelepiped), and Rs 
(cylinder), respectively. By knowing Tm(as or Rs) and ∆Hm(as or Rs), it was, then, possible to 
develop and compare the corresponding trends Tm(VC) and ∆Hm(VC) for the three different 
considered geometries. Model features were explored by considering nimesulide (NIM) as a proof 
of concept (see Table 4.1.1 displaying the NIM physicochemical parameters required for the 
simulations). Indeed, NIM is a typical non-steroidal anti-inflammatory drug characterized by a 
low bioavailability due to its low water solubility (Davis and Brogden, 1994; Cignarella et al., 
1996). Figure 4.1.1, showing the Tm and ∆Hm depression in the case of parallelepiped-shaped 
crystals characterized by Xnc = 1 and a square basis (β = as/bs = 1), clarifies the effect of the shape 
ratio ξ (= cs/as) (the representation is inferiorly limited to the volume of approximately four NIM 
unit cells ≈ 11 nm3). It is observable that the shape ratio ξ affects in a qualitatively similar manner 
both Tm and ∆Hm, even if its effect appears more accentuated for Tm. In particular, Figure 4.1.1 
shows that, at fixed crystal volume (VC), platelet nanocrystals (ξ = 0.01) are characterized by lower 
Tm and ∆Hm than rod-shaped (ξ = 100) nanocrystals. In addition, both of them show lower Tm and 
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∆Hm than cubic nanocrystals. Conversely, at fixed Tm or ∆Hm, cubic crystals are characterized by 
the smallest dimensions among the other shapes (rods and platelets). It is worth mentioning that 
the 
Table 4.1.1. Nimesulide physicochemical parameters. UCS indicates the diameter of the unit cell 
imagined as a sphere, Mw is the molecular weight, slγ
∞
, 
lvγ
∞
, and svγ
∞
 are, respectively, the solid-
liquid, liquid-vapor, and solid-vapor surface energy referring to a plane surface (infinite curvature 
radius), δ0 is Tolman’s length, ρs and ρl are, respectively, the solid and liquid density, Tm∞ and 
∆Hm∞ are, respectively, the melting temperature and enthalpy of the infinitely large crystal, ∆CP 
is the difference between the liquid and solid specific heat at constant pressure, Vm is the molar 
volume, while Cs is the solubility in water (37°C) (data from Chiarappa et al., 2017). 
Formula C13H12N2O5S 
UCS (nm) 1.74 
Mw (–) 308.51 
slγ
∞
 (J/m2) 0.0133 
lvγ
∞
 (J/m2) 0.0433 
svγ
∞
 (J/m2) 0.0576 
δ0 (nm) 0.2385 
ρs (kg/m3) 1490.0 
ρl (kg/m3) 1343.7 
Tm∞ (°C) 148.7 
∆Hm∞ (J/kg) 108720 
∆CP (J/kg°C) 333.3 
Vm (m3/mole) 192.10-6 
Cs (µg/cm3) – 37°C, pH 1.2 11.8 ± 0.5 
Cs (µg/cm3) – 37°C, pH 7.5 104 ± 12 
 
the relation existing between Tm and VC is substantially compatible with the outcomes of the 
nucleation theory, which allows determining the size (VC) of the smallest nucleus (namely a cluster 
of molecules) which a crystal originates from (Hamilton et al., 2012). 
This model output is explicable by remembering the theoretical expression of the melting 
temperature/enthalpy dependence on the surface and bulk atoms number in the case of 
parallelepiped-shaped nanocrystals theorized by Magomedov (Magomedov, 2004; Magomedov, 
2011). This, fundamentally, underlines the importance of the ratio between the surface and bulk                
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. 
 
Figure 4.1.1. Effect of the shape ratio ξ = cs/as on the melting temperature Tm (left vertical axis, 
black lines) and enthalpy ∆Hm (right vertical axis, gray lines) of parallelepiped-shaped 
nanocrystals, when assuming the nanocrystals mass fraction Xnc = 1 and β = as/bs = 1. as, bs, and 
cs are the dimensions of the parallelepiped-shaped crystal, while VC is the crystal volume. The 
shaded parallelepipeds qualitatively represent the shape of the crystals pertaining to the curve they 
intersect. 
 
Figure 4.1.2. Equation 4.1.1 plot showing the dependence of the dimensionless ratio between 
crystal surface (As) and volume (Vs) on the shape ratio ξ = cs/ac at constant volume. The value β = 
bs/ac = 1 was assumed to perform a coherent connection with Figure 4.1.1. The shaded 
parallelepipeds qualitatively represent the shape of the crystals pertaining to the different ξ values. 
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atoms/molecules. Indeed, at constant volume (VC), cubic crystals show the minimum surface-
volume ratio with respect to the other conformations (rods and platelets), as witnessed by eq 4.1.1 
and Figure 4.1.2: 

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++=
β
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β
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33 2
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s
s
V
Aac
                                                                                             (4.1.1) 
where ac stands for the side of the cube, while As and Vs (= VC = acbccc) are the surface and the 
volume of the crystal, respectively. Additionally, the higher surface-volume ratio shown by 
platelet crystals with respect to rod crystals (Figure 4.1.2) explains why platelet crystals are 
characterized by lower Tm and ∆Hm in comparison to rod crystals. In the case of cylindrical 
crystals, model 
 
Figure 4.1.3. Effect of the shape ratio λ = Ls/Rs on the melting temperature Tm (left vertical axis, 
black lines) and enthalpy ∆Hm (right vertical axis, gray lines) of cylindrical nanocrystals, when 
assuming the nanocrystals mass fraction Xnc = 1. Ls and Rs are the length and the radius of the 
cylindrical-shaped crystal, while VC is the crystal volume. The shaded cylinders qualitatively 
represent the shape of the crystals pertaining to the curve they intersect. 
 
crystals, model results (eqs 2.2.3.6
 
–
 
2.2.3.7) are qualitatively similar to those found for 
parallelepipeds. Indeed, Figure 4.1.3, showing the effect of the shape ratio λ on Tm and ∆Hm 
4-5 
 
depression, reveals that rod-shaped (λ = 200; black/gray solid thickest lines) and platelet-shaped 
(λ = 0.02; black/gray dotted lines) crystals are characterized by more consistent reductions of Tm 
and ∆Hm than those referring to the equilateral cylinder (λ = 2; black/gray solid thinnest lines) (the 
representation is inferiorly limited to the volume of approximately four NIM unit cells ≈ 11 nm3). 
However, since the surface-volume ratio of the equilateral cylinder is close to the one of rod-
shaped crystals (see Figure 4.1.4): 
33
2s
s
s
λ4
λ
4
+=
V
RA
                                                                                                                 (4.1.2) 
the Tm and ∆Hm trends of rod-shaped crystals are less detached from those of the equilateral one 
differently from the case of parallelepiped-shaped crystals (Figure 4.1.1). It is important to remind 
that 
 
Figure 4.1.4. Equation 4.1.2 plot showing the dependence of the dimensionless ratio between 
crystal surface (As) and volume (Vs) on the shape ratio λ = Ls/Rs at constant volume. The shaded 
cylinders qualitatively represent the shape of the crystals pertaining to the different λ values. 
 
that the value of Xnc appears to slightly affect the results shown in Figure 4.1.1 and Figure 4.1.3, 
where Xnc = 1 was considered. However, the reduction of Xnc is reflected in a decrease of both Tm 
and ∆Hm, being VC the same. 
It is now interesting to evaluate the effect of nanocrystals shape (sphere, cube (ξ = β = 1), and 
equilateral cylinder (λ = 2)) on Tm and ∆Hm depression. Figure 4.1.5, concerning the melting 
4-6 
 
process of spherical, cubic, and (equilateral) cylindrical crystals, clarifies that, at equal crystal 
volume (VC), Tm and ∆Hm of cubic nanocrystals are lower than those of cylindrical nanocrystals. 
In turn, cylindrical nanocrystals show lower Tm and ∆Hm with respect to spherical nanocrystals. 
The explanation of this behavior relies on both the dimensionless surface-volume ratio (cube → 
3; equilateral cylinder → 2; sphere → 3) and the reduction of surface energy with surface curvature 
(1/r, see eq 2.2.1.3). Indeed, not only cubic crystals are characterized by the highest value of the 
surface-volume ratio but they also show the highest surface energy as they are constituted by plane 
surfaces (curvature = 1/r → 0). 
 
Figure 4.1.5. Effect of geometry (sphere, cube (ξ = β = 1), equilateral cylinder (λ = 2)) on melting 
temperature Tm (left vertical axis, black lines) and enthalpy ∆Hm (right vertical axis, gray lines) 
depression, when assuming the nanocrystals mass fraction Xnc = 1. The representation is inferiorly 
limited to the volume of approximately four nimesulide unit cells ≈ 11 nm3. 
 
On the contrary, spherical crystals, although characterized by the same surface-volume ratio (3), 
suffer from the reduction of surface energy with curvature, this last one increasing as crystal radius 
decreases. Equation 2.27b clarifies that, for vanishingly small values of γlv and γsl, Tm and ∆Hm are 
independent of sphere radius. Cylindrical crystals are in between the spherical and cubic ones as 
they are characterized by the smallest surface-volume ratio, but the effect of curvature affects only 
the lateral surface and not the two bases. 
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4.2 Practical Results 
The findings of this study are reflected in two crucial and practical aspects characterizing 
nanocrystals based delivery systems, i.e. the nanocrystals size distribution inside a polymeric 
carrier and nanocrystals water solubility. For this purpose, it is worthwhile to take into 
consideration the work performed by Coceani and collaborators (Coceani et al., 2012) on NIM 
loaded into a stabilizing polymeric matrix constituted by cross-linked polyvinylpyrrolidone (PVP 
Cl-M), a white, tasteless, odorless, and water-insoluble powder obtained by popcorn 
polymerization. 
NIM/PVP Cl-M physical mixtures (ratio 1:3, w/w) were co-ground for 0.5, 1, 2, and 4 h in a 
planetary mill rotating at 350 rpm and, then, analyzed with a differential scanning calorimeter 
(DSC) in order to determine the fraction of the original macrocrystalline drug (Xmc) and that of the 
newly formed nanocrystalline (Xnc) or amorphous (Xam) one. 
 
Figure 4.2.1. Pure nimesulide (dotted line), 0.5 h (thick line), and 1 h co-ground system (thin line) 
thermograms performed by differential scanning calorimetry. The reduction of melting 
temperature Tm and enthalpy cgmH∆  for the two co-ground systems is clearly evident (from Coceani 
et al., 2012). 
 
Figure 4.2.1 displays the pure NIM melting peak (dotted line; Tm∞ = 148.7°C, ∆Hm∞ = 109000 
J/kg) and the DSC profiles of two co-ground systems (0.5 h, thick line; 1 h, thin line). While the 
0.5 h co-ground system shows a melting peak at 129.6°C requiring 8700 J/kg, the 1 h one decreases 
to 126.6°C and 8500 J/kg. Figure 4.2.1 clarifies that simply 0.5 h is sufficient to completely destroy 
the original macrocrystals into nanocrystals (Xmc = 0), as no thermal event occurs at the pure NIM 
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melting temperature. Similarly, Figure 4.2.2 displays the DSC profiles relative to two other co-
ground systems (2 h, thick line; 4 h, thin line). The 2 h DSC curve shows a melting event at 118°C  
 
Figure 4.2.2. Pure nimesulide (dotted line), 2 h (thick line), and 4 h co-ground system (thin line) 
thermograms performed by differential scanning calorimetry. The reduction of melting 
temperature Tm and enthalpy cgmH∆  is more pronounced than the 0.5 and 1 h co-ground systems 
(from Coceani et al., 2012). 
 
Figure 4.2.3. Comparison between the XRPD pattern relative to a PVP Cl-M/nimesulide (3/1, 
w/w) physical mixture (thin line) and the 2 h co-ground system (thick line). No substantial 
modifications of the XRPD pattern derive from co-grinding, meaning that no drug polymorphs 
were formed (from Coceani et al., 2012). 
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requiring 5100 J/kg, while the 4 h curve is characterized by a melting peak occurring at 112 °C 
after 2500 J/kg heat. Figure 4.2.3 shows the comparison between the X-rays powder diffraction 
(XRPD) patterns relative to the physical mixture and the same mixture after two-hour milling. It 
is possible to notice that no substantial shift of the typical NIM diffraction peaks (occurring at 2θ 
= 5, 11, 12, 18, 19.5, 21, 22, 23, and 24.3) arises. As analog diffraction patterns may be obtained 
for the other grinding times (0.5, 1, and 4 h), it was concluded that no polymorphs were generated 
during grinding. 
Furthermore, the determination of the aforementioned drug fractions, in the case of spherical 
crystals, was also theoretically achieved by means of the iterative simultaneous numerical solution 
of eqs 2.2.1.8 and 2.2.1.9, explained in paragraph 2.2.1, which starts by making a reasonable first 
guess of Xnc. Once a first estimation of the drug specific melting enthalpy per unit mass (∆Hm) as 
a function of drug crystal radius is obtained, Xnc is recalculated according to: 
( )
( ) ( )TR HHH
HX
∆+∆−∆
∆
=
∞ sdd
mix
m
d
cg
m
nc
ωω
ω
                                                                                      (4.2.1) 
where cgmH∆  is the experimental co-ground system specific melting enthalpy per unit mass (owed 
to drug melting only, as the polymeric carrier is amorphous) at Tm, i.e. the melting temperature of 
drug nanocrystals with radius Rs, ωd is the drug mass fraction characterizing both the physical 
mixture and the co-ground system, mixm∞∆H  is the experimental physical mixture specific melting 
enthalpy per unit mass at Tm∞, i.e. drug macrocrystals melting temperature, while 
sR
H∆  and ∆HT 
are, respectively, the second and the third term in the right-hand side of eq 2.2.1.9. If the relative 
difference between Xnc calculated according to eq 4.2.1 and the initially guessed one is lower than 
a fixed tolerance, the iterative procedure ends by providing the theoretical value of Xnc. On the 
contrary, the procedure is repeated by assuming the new value of Xnc as: 
( ) newncoldncnc λλ1 XXX +−=                                                                                                          (4.2.2) 
where λ is a relaxation parameter ranging from 0 to 1, old
ncX  and newncX  represent, respectively, the 
Xnc value assumed at the beginning of the ith iterative loop and that recalculated according to eq 
4.2.1 at the end of the same loop. The procedure is repeated until the aforesaid relative difference 
test is passed. Obviously, the determination of Xmc simply requires the evaluation of: 
( )
( )dmixm
d
cg
m
mc
ω
ω
∞
∞
∆
∆
=
H
HX
                                                                                                                  (4.2.3) 
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where cgm∞∆H  is the experimental co-ground system specific melting enthalpy per unit mass at Tm∞. 
Xam is, finally, determined as: 
mcncam 1 XXX −−=                                                                                                                  (4.2.4) 
Once ∆Hm, Tm, and Xnc are obtained from the previous iterative procedure, it is possible to evaluate 
the nanocrystals size distribution. The starting point is the definition of the melting enthalpy (
nc
mH∆ ) of the mass of drug nanocrystals with a radius ranging from Rs to (Rs + dRs): 
( ) ncsmncm dd VHH ρ∆=∆                                                                                                             (4.2.5) 
where dVnc is the volume occupied by nanocrystals with a radius ranging between Rs and (Rs + 
dRs). Equation 4.2.5 yields: 
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where t is time, Q&  is the heat flow recorded by DSC, and v is DSC heating rate. The function 
dTm/dRs may be numerically obtained from Tm(Rs). Consequently, nanocrystals differential 
volume distribution (f) is given by: 
( )
s
s
nc
s
nc
s
d
d
d
d
d
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R
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
=
                                                                                                            (4.2.7) 
where max
sR  and minsR  represent, respectively, the maximum and the minimum value assumed by 
drug nanocrystals radius. 
Figure 4.2.4, displaying the results of the exposed numerical approach to the aforesaid four co-
ground systems on the basis of the values in Table 4.1.1, shows how Xnc decreases with grinding 
time. Although there is no difference between the 0.5 h and 1 h processed powders in terms of Xnc, 
interestingly, the last ones are characterized by smaller dimensions, as witnessed by the left shift 
of f. Thus, in this case, the difference of mechanical energy provided to the co-ground mixture 
translates into a further reduction of Rs without significant effect on Xnc. Further increases of 
grinding time determine both Xnc and Rs reductions. Moreover, longer grinding times are reflected 
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in a progressive narrowing of f as clearly visible in Figure 4.2.4. It is worth noticing that, for the 
four considered systems, Rs ranges from about 0.8 nm to 3.5 nm. 
 
Figure 4.2.4. Nanocrystals fraction (Xnc) and differential size distribution (f) in the four considered 
co-ground systems. Rs is nanocrystals radius (from Coceani et al., 2012). 
 
Figure 4.2.5. Effect of nanocrystals geometry (sphere, cube (ξ = β = 1), and parallelepiped (ξ = 
0.01 and 100; β = 1)) on their size distribution (f) referring to the nimesulide-polyvinylpyrrolidone 
(1:3) system described in Coceani et al., 2012 after one-hour co-grinding. Rsphere is the radius of 
the equivalent sphere sharing the same volume of parallelepiped-shaped nanocrystals. Nimesulide 
unit cell half dimension corresponds to Rsphere = 0.77 nm. 
 
It is interesting to evaluate how crystal geometry may affect the results depicted in Figure 4.2.4. 
0
0.5
1
1.5
2
2.5
0 1 2 3 4
f(R
s)(
1/
n
m
)
Rs(nm)
Xnc[0.5h] = 0.41 ± 0.01
Xnc[1h] = 0.41 ± 0.01
Xnc[2h] = 0.34 ± 0.01
Xnc[4h] = 0.15 ± 0.03
4-12 
 
Hence, the attention was focused on the one-hour co-ground system by assuming that NIM 
nanocrystals are square base parallelepipeds (β = 1) characterized by different shape factors (ξ). 
For this purpose, it is more significant to express nanocrystals size distribution (f(1/nm)) as a 
function of the radius, Rsphere, of the equivalent sphere sharing the same volume of the considered 
crystal. The inspection of Figure 4.2.5 reveals that both the distribution wideness and the peak 
position increase when considering, in order, spherical, cubic, and parallelepiped (rods β = 1 and 
ξ = 100; platelets β = 1 and ξ = 0.01) nanocrystals. This result sounds reasonable as, in the case of 
spherical crystals, the size distribution lies very close to the physical limit of NIM nanocrystals, 
i.e. one-half of NIM unit cell (0.77 nm). On the contrary, when cubic nanocrystals are considered 
(whose shape is close to that of the real NIM crystals as predicted by the WinXMorph software 
(Kaminsky, 2007)), the distribution moves towards larger radii. Finally, increasingly larger radii 
are considered by the rod and platelet distributions. These findings could contribute to explain 
why, when presuming crystals to be spherical, the estimation of crystals size by DSC is usually 
lower than that performed by means of the X-Rays approach (Hasa et al., 2013; Hasa et al., 2016). 
 
Figure 4.2.6. Size distribution assuming NIM nanocrystals to be spherical (thick line) or cubic (ξ 
= β = 1) in the case of the 0.5 h co-ground system. Rsphere is the radius of the equivalent sphere 
sharing the same volume of the considered crystal. 
 
Finally, Figures 4.2.6 – 4.2.9 exhibit the comparison between the nanocrystals size distribution 
assuming NIM nanocrystals to be spherical (Coceani et al., 2012) or cubic ( the result of the present 
study) for the considered four co-ground systems. It is evident that, no matter how co-grinding 
time is long, size distribution shifts towards larger radii of the equivalent sphere (Rsphere). On the 
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contrary 
 
Figure 4.2.7. Size distribution assuming NIM nanocrystals to be spherical (thick line) or cubic (ξ 
= β = 1) in the case of the 1 h co-ground system. Rsphere is the radius of the equivalent sphere 
sharing the same volume of the considered crystal. 
 
Figure 4.2.8. Size distribution assuming NIM nanocrystals to be spherical (thick line) or cubic (ξ 
= β = 1) in the case of the 2 h co-ground system. Rsphere is the radius of the equivalent sphere 
sharing the same volume of the considered crystal. 
 
contrary, crystal shape plays a minor role in the determination of Xnc. Indeed, regardless of co-
grinding time, Xnc coincides with the values displayed in Figure 4.2.4 when cubic, rod-like, or 
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platelet-like nanocrystals are considered. 
 
Figure 4.2.9. Size distribution assuming NIM nanocrystals to be spherical (thick line) or cubic (ξ 
= β = 1) in the case of the 4 h co-ground system. Rsphere is the radius of the equivalent sphere 
sharing the same volume of the considered crystal. 
 
When moving to the effect of geometry on nanocrystals water solubility, it is useful to recall the 
relation existing between solubility and Tm or ∆Hm (eqs 2.3.11 and 2.3.12). This thermodynamic 
approach leads to the interesting conclusion that the solute solubility in the liquid phase also 
depends on the Tm and ∆Hm of the solid phase. In particular, the lower Tm and ∆Hm the higher the 
solubility of the solid phase in the liquid one, as shown by Figure 4.2.10 that depicts eqs 2.3.11 
and 2.3.12 outcomes regarding the solubility trend of spherical and cubic NIM nanocrystals (Xnc 
= 1) as a function of nanocrystals size up to NIM unit cell volume (2.77 nm3), a value 
corresponding to Rsphere = 0.87 nm. Figure 4.2.10, based, for the sake of simplicity, on the 
assumption that γd is almost constant with concentration, allows evaluating the ratio Cs/Cs∞, where 
Cs∞ is the mass/volume solubility of the infinitely large NIM crystal. The choice of the cubic shape 
is dictated by the approximately cubic morphology of the real NIM nanocrystals as predicted by 
the WinXMorph software (Kaminsky, 2007). It is clear that cubic shape implies a more 
pronounced increase of solubility since cubic crystals are characterized by lower Tm and ∆Hm with 
respect to spherical crystals of the same volume (see Figure 4.1.5). Interestingly, the maximum 
theoretical solubility increase occurring for Rsphere → 0.87 nm (approximately eightfold) is 
compatible with the solubility increase of amorphous drugs (not chemically too dissimilar to NIM) 
lying in the range 10 – 100 (amorphous drug is expected to be more soluble than nanocrystalline 
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drug) (Murdande et al., 2010; Bahl and Bogner, 2006). 
 
Figure 4.2.10. Effect of nanocrystals geometry (sphere, cube (ξ = β = 1) on the ratio between the 
solubility of nimesulide nanocrystals (Cs) and that of the infinitely large nimesulide crystal (Cs∞), 
when assuming the nanocrystals mass fraction Xnc = 1. Rsphere is the radius of a sphere sharing the 
same volume of the cubic nanocrystal. The simulation is arrested at the value corresponding to 
nimesulide unit cell volume (2.77 nm3), i.e. Rsphere = 0.87 nm. 
 
4.3 Conclusions 
The thermodynamic model developed in this work allows evaluating the effect of size and shape 
on Tm and ∆Hm of organic (drug) nanocrystals. In particular, the differences existing among 
spherical, cylindrical, and parallelepiped-shaped nanocrystals, characterized by different shape 
ratios (from needles to platelets), are explained in terms of the ratio between the number of the 
surface and bulk molecules. Indeed, the higher this ratio the higher the Tm and ∆Hm reductions are 
and, consequently, the higher the drug solubility is. As a drug solubility increase is reflected in a 
drug bioavailability enhancement, the considerable practical effect of nanocrystals geometry on 
nanocrystals based delivery systems clearly emerges. 
Model reliability, tested in the case of a well-known poorly water-soluble drug (nimesulide, a non-
steroidal anti-inflammatory drug), is supported by the fact that the predicted solubility increase is 
physically sound in relation to the solubility of the amorphous drug, which is expected to be 
considerably higher. In addition, model reliability was also proved by the results obtained from a 
molecular dynamics approach developed in chapter 3, which confirms the Tm and ∆Hm reduction 
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predicted by the thermodynamic model and the effect of shape ratio variation. Accordingly, this 
model may be considered a reliable tool for the characterization/design of nanocrystals based 
delivery systems (determination of Xnc and nanocrystals size distribution in polymer-drug systems) 
and for the evaluation of nanocrystals solubility increase, an aspect of paramount importance for 
the bioavailability enhancement of poorly water-soluble drugs. In addition, as it relies on 
thermodynamics, the developed model potentially holds for every drug and its polymorphic forms 
which may be considerably significant in the pharmaceutical field. Clearly, it requires the 
knowledge of a certain number of fundamental physical parameters such as surface tension, 
density, and Tm∞/∆Hm∞ of the specific drug/polymorphic species. Finally, as it evidences the key 
role played by nanocrystals geometry, the presented model possible development may imply a 
shift from the physically sound but rather simple parallelepiped shape to a more complex prismatic 
one. Indeed, prisms may approximate in a more realistic way the actual nanocrystals shape. 
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CHAPTER 5 
 
RELEASE AND ABSORPTION 
 
 
5.1. Physiologically-based Pharmacokinetic Model 
The mathematical representation of the human body is essentially based on the physiologically-
based pharmacokinetic (PBPK) model presented by Di Muria and co-workers (Di Muria et al., 
2010). The gastrointestinal (GI) tract is described by a continuous hollow cylinder subdivided into 
three zones: gastric lumen (GL), small intestine lumen (SIL), and large intestine lumen (LIL) (see 
Figure 5.1). The physiological and morphological differences (for instance, pH and internal radius) 
in the GI tract are considered by means of different permeability (PGL, PSIL, and PLIL, respectively), 
drug solubility (CsGL, CsSIL, and CsLIL, respectively), and internal radius ( iGLR , iSILR , and iLILR , 
respectively) for each zone. The GI tract is crossed by the release environment, an aqueous volume 
(Vr) containing the delivery system (an ensemble of non-eroding polydispersed polymeric particles 
loaded with drug), which, due to peristalsis, flows downward from GL to SIL and, eventually, to 
LIL. For modeling purposes, it is assumed that the release environment shape is the one of a hollow 
cylinder whose external radius coincides with iGLR , 
i
SILR  or 
i
LILR , while the internal radius (Ri) may 
vary from zero to iGLR , 
i
SILR  or 
i
LILR . When Ri equals zero, the release environment is simply a 
cylinder of radius iGLR , 
i
SILR  or 
i
LILR  depending on its GI position. When, on the contrary, Ri is 
greater than zero, the release environment assumes the shape of a hollow cylinder. In both cases, 
the length of the release environment is defined by (see Figure 5.1): 
( )2i2ij rj π RR
VL
−
=           (j = GL, SIL, LIL)                                                                              (5.1.1) 
It is, thus, evident that the choice of Ri serves to define the (time/position-dependent) contact area 
5-2 
 
between the release environment and the GI tract mucosa. Consequently, Ri may be considered a 
model fitting parameter. When lacking further physiological information, the most obvious Ri = 0 
condition was considered in this work. 
 
 
 
Figure 5.1. Schematic representation of the physiologically-oriented mathematical model. The 
release environment (volume Vr), due to peristalsis, flows from the gastric lumen (GL) to the small 
(SIL) and, eventually, large (LIL) intestine. After leaving the delivery system (a non-eroding 
polydispersed ensemble of polymeric particles), the drug spreads through the release environment 
fluids and, then, may permeate, by passive absorption, GL, SIL, and LIL mucosae, reaching the 
gastrointestinal circulatory system (GICS). Afterward, the drug reaches, through the portal vein 
(PV), the liver where undergoes metabolic/biliary clearance (CLH) or joins the plasma through the 
hepatic vein (HV). From the plasma, the drug may reach the less perfused tissues, return to the 
liver through the hepatic artery (HA) or to CIGS through PV. Adapted from Di Muria et al., 2010. 
 
Due to the well-known differences in the morphology/physiology of each zone, it is supposed that 
the release environment velocity (vre) may vary along the GI tract by setting three different 
residence times (tGL, tSIL, and tLIL, respectively), one for each zone. The position in the GI tract 
(Pos) and vre are connected by the following relation: 
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∫=
t
tvP
0
reos d                                                                                                                              (5.1.2) 
where t is time. Thus, by assuming vre as a constant, the transit time (tt) of the whole GI tract (Lt) 
is: 
re
t
t
v
L
t =
                                                                                                                                     (5.1.3) 
Alternatively, by always assuming vre as a constant, after a certain time t, the position reached by 
the release environment is: 
tvP reos =                                                                                                                                   (5.1.4) 
After being released, the drug may undergo elimination in the release environment (the coefficient 
of elimination ( REelk ) is dimensionally an inverse of time) and cross, due to passive diffusion, the 
GI mucosa depending on the local permeability, which is a function of the Vr position in the GI 
tract. Then, the drug reaches the gastrointestinal circulatory system (GICS), a compartment 
introduced in pharmacokinetic (PK) modeling by Di Muria and co-workers (Di Muria et al., 2010) 
for the first time. Fundamentally, it corresponds to the ensemble of the mesenteric artery (MA), 
portal vein (PV), and microcirculatory GI vessels. This section of the whole circulatory system 
behaves differently from the remaining one. In the case of parenteral administration, MA 
transports the drug toward the GI tract. In the case of enteral administration, on the contrary, PV 
transports the drug from the GI tract toward the liver (where the drug undergoes the so-called first-
pass effect), from which it reaches the remaining part of the circulatory system (plasma) and the 
other tissues. The introduction of GICS allowed transforming the very detailed PK model proposed 
by Jain and co-workers (Jain et al., 1981) (consisting in 21 compartments and 38 ordinary 
differential equations with approximately 100 parameters) into a simple and effective model (7 
compartments and 7 ordinary differential equations with about 20 parameters). GICS is assumed 
as a well-stirred environment characterized by a constant volume (VGICS) and a time-dependent 
drug concentration (CGICS). 
PV ensures the drug convective transport (blood volumetric flow, QPV) from GICS to the liver 
(volume, VL). The drug concentration in the liver (CL) varies due to the hepatic clearance (CLH) 
(dimensionally a volumetric flow) and the convective transport by the hepatic vein (HV) and artery 
(HA). HV connects the liver to the highly perfused tissues and organs (where the drug 
concentration is assumed equal to the plasma one) by a blood volumetric flow (QHV), while HA 
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returns the drug from the plasma to the liver (blood volumetric flow, QHA). Once in the plasma 
(volume, VP), the drug may be eliminated (the coefficient of elimination ( *elk ) is dimensionally a 
volumetric flow), convectively returned to GICS through PV, and exchanged with the poorly 
perfused tissues and organs (“tissues” in Figure 5.1). The drug exchange between plasma and 
tissues (volume, VT) is ruled by the mass transfer coefficient from plasma to tissues ( *PTk , 
dimensionally a volumetric flow) and the reverse one from tissues to plasma ( *TPk , dimensionally 
a volumetric flow). However, the model equations may be rewritten with the more common drug 
elimination coefficient ( P*elel Vkk = ) and plasma-tissues exchange constants ( P*PTPT Vkk = ; 
P
*
TPTP Vkk = ), which are dimensionally an inverse of time. Accordingly, the PBPK model, 
depicted in Figure 5.1, is mathematically represented by the following system of ordinary 
differential equations, where t is the independent variable: 
( ) ( )GICSP
GICS
PV
GICSr
GICS
jjGICS
d
d CC
V
QCC
V
PA
t
C
−+−=
                                       GICS                      (5.1.5) 
L
L
LHHV
P
L
HA
GICS
L
PVL
d
d C
V
CQC
V
QC
V
Q
t
C





 +
−+=                                           LIVER                   (5.1.6) 
( ) TTPPPTelP
P
HAPV
L
P
HVP
d
d CkCkkC
V
QQC
V
Q
t
C
++−




 +
−=                           PLASMA              (5.1.7) 
TTPPPT
T
d
d FCkFCk
t
C
−=                                                                           TISSUES              (5.1.8) 
PPelLLHr
re
elr
el
d
d CVkCCCkV
t
M
++=
                                                                                       (5.1.9) 
where jjj π2 LRA =  (j = GL, SIL, LIL), LILSILGLj  , , PPPP = , and TP VVF = . 
Equation 5.1.5 allows the calculation of CGICS, eq 5.1.6 evaluates CL, eq 5.1.7 determines the 
plasma drug concentration (CP), eq 5.1.8 calculates the tissues drug concentration (CT), and, 
finally, eq 5.1.9 allows the determination of the amount of the drug eliminated in the release 
environment, liver, and plasma. The inspection of eq 5.1.5 reveals that the drug diffusive flux from 
the release environment to GICS requires the knowledge of the drug concentration in the release 
environment (Cr), which is disclosed in the following. 
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5.2. Delivery Model 
The developed model assumes that the drug release kinetics is essentially determined by (i) the 
polymeric particles size distribution in the dry state; (ii) the particle swelling after the contact with 
the release environment fluids (particle erosion is considered negligible for highly cross-linked 
polymeric networks); (iii) the drug dissolution and diffusion inside the particles; and (iv) the 
possible drug recrystallization in the release environment fluids. 
The first point is described by assuming that the dry particles size distribution is conveniently 
represented by Weibull’s distribution function (Grassi et al., 2006):  
δ






η
−
−
−=
minp2
0
e1
RR
V
V
                                                                                                                 (5.2.1) 
where Rp and Rmin are, respectively, the generic and the minimum particle radius, η and δ are two 
parameters regulating Weibull’s size distribution, while V0 and V are the volume occupied by all 
the polymeric particles and the one occupied by the particles of a radius less than or equal to Rp, 
respectively. In order to consider particles polydispersity, Weibull’s size distribution is subdivided 
into Nc classes depending on particles radius. Accordingly, the particles of the ith class (i ranging 
from 1 to Nc) share the same radius Rpi. 
For each class, the swelling process (ii) may be evaluated by the following mass balance referred 
to the swelling agent (solvent): 
( )i2i
i
2
i
pi 1 JR
RRt
C
−
∂
∂
=
∂
∂
                                                                                                          (5.2.2) 
vifii JJJ +=                                                                                                                            (5.2.3) 
i
pi
ffi R
C
DJ
∂
∂
−=
                                                                                                                         (5.2.4) 
i
i
vvi R
DJ
∂
σ∂
−=
                                                                                                                         (5.2.5) 
where Cpi is the local solvent concentration, t is time, Ri is the radial coordinate, Jfi and Jvi indicate 
the fickian and non-fickian components of the solvent flux, respectively, Df and Dv are the fickian 
and viscoelastic (dimensionally a time) diffusion coefficients of the solvent, respectively, while σi 
is the stress tensor generated by the incoming solvent in the film network. Fundamentally, eq 5.2.2 
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derives from the assumption that the solvent chemical potential depends on both Cpi and σi. The 
existence of two contributions in the solvent flux is due to the viscoelasticity of the polymer-
solvent system, i.e. polymeric chains undergo rearrangements over time (relaxation) after the 
solvent uptake. Hence, Jvi represents a delayed flux induced by the polymer-solvent system 
viscoelastic character. Despite the complexity of the theoretical description of the stress and 
deformation states in the swelling matrix, it is generally assumed that the stress state may be 
approximated by a scalar viewed as an osmotically induced viscoelastic swelling pressure related 
to the trace of the stress tensor (Swaminathan and Edwards, 2004). Indeed, one-third of the tensor 
trace represents the normal stress of the tensor spherical (or hydrostatic) part. On a more physical 
plane, σi may be interpreted as the polymeric network reaction to its enlargement induced by the 
solvent uptake. Moreover, by following Ferreira and coworkers’ suggestions (Ferreira et al., 2014), 
σi may be described by the generalized Maxwell’s model, a combination, in series, of one elastic 
and Nv viscoelastic elements: 
∑
=
+=
v
1j
jii0i σσσ
N
                                                                                                                      (5.2.6) 
ii0i0 εσ E−=                                                                                                                              (5.2.7) 
ji
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−=+                  (j from 1 to Nv)                                                                     (5.2.8) 
ms
pis
mjji
ρ
ρ
C
C
EE
−
−
=
                      (j from 0 to Nv)                                                                     (5.2.9) 
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
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


−
−
=
C
C
                                                                                                             (5.2.11) 
where σ0i and E0i are, respectively, the stress and the elastic modulus of the elastic element, εi is 
the local deformation, ρs is solvent density, σji, Eji, and λji are, respectively, the stress, the elastic 
modulus, and the relaxation time of the generic viscoelastic element, k is a model parameter, Cpe 
indicates the solvent concentration in the fully swollen particle (thermodynamic equilibrium), 
while λej is the value assumed by λji at equilibrium (i.e. when Cpi = Cpe). The “minus” sign 
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appearing in eqs 5.2.7 and 5.2.8 remembers that stress opposes deformation. The linear 
dependence of Eji on Cpi (eq 5.2.9) is a direct consequence of Flory’s theory (Flory, 1953). Indeed, 
according to Flory, the crosslink density (ρx), i.e. the moles, per unit volume, of junctions among 
the different chains constituting the polymeric network, varies linearly with Cpi. Furthermore, by 
resorting to the same theory, the elastic modulus (Young’s modulus) is proportional to ρx by 3RT 
(R = gas constant, T = absolute temperature). Thus, in the present work, it is assumed that the Eji 
dependence on Cpi may be described by eq 5.2.9, where Cm is the uniform solvent concentration 
in the polymeric matrix corresponding to the condition of the (rheological) determination of each 
Emj. Finally, eq 5.2.11 is derived from the deformation tensor in the simplifying hypothesis of 
incompressible materials and vanishingly small deformation gradient. In addition, eq 5.2.11 
implies that no deformation (and, therefore, stress) occurs when Cpi equals the solvent 
concentration (Csw) corresponding to the crosslinking conditions (if Csw = 0, the expression 
employed by Ferreira and collaborators (Ferreira et al., 2015) may be derived). A Fujita type 
dependence for the fickian diffusion coefficient of the solvent was considered (Grassi et al., 2007):  








−−
=
pe
pi1
e
ff e
C
Cf
DD                                                                                                                   (5.2.12) 
where efD  is the equilibrium value of Df (i.e. when Cpi = Cpe) and f is a model parameter to be 
determined.
 
Although other possibilities exist (Ferreira et al., 2015), the evaluation of the 
viscoelastic diffusion coefficient was performed according to Darcy’s theory (Truskey et al., 
2004), which assimilates a polymeric network to a porous system:
 
( ) pi2s
2
f
3
v
α1η4
α C
g
rD
−
=           





ρ
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s
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                                                                                  (5.2.13) 
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where α is system porosity, ηs is the water viscosity at a fixed temperature, and rf is the radius of 
the chains (assumed cylindrical) constituting the polymeric network. Fundamentally, Darcy’s 
theory provides a sigmoidal increase (in a bilogarithmic diagram) of Dv with Cpi (see Figure 5.2). 
The swelling part of the model is completed by assuming the solvent-polymer mix ideal, i.e. the 
particle volume may be computed by summing the polymer, drug, and solvent volumes. In order 
to consider particles swelling, an isotropic volume increase was introduced (Grassi et al., 2007):
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Figure 5.2. Dependence of the viscoelastic diffusion coefficient (Dv) on the local solvent 
concentration in the matrix (Cpi) according to Darcy’s law for different polymeric chain radii (rf). 
Each simulation assumes water as the swelling fluid (ηs = 10–3 Pa; ρs = 1000 kg/m3). 
 
where dRi indicates the thickness of the generic spherical shell of a particle, 
0
idR  is the dRi value 
in the initial dry state, ρd is drug density, Ci is the local concentration of the dissolved drug, amdiC , 
nc
diC , and 
mc
diC  are, respectively, the position-dependent concentrations of the undissolved drug in 
the amorphous, nanocrystalline, and microcrystalline states. Equation 5.2.2 may be solved by 
assuming that particles are initially solvent-free, the solvent flux is null in the particle center for 
symmetry reasons, and the solvent concentration at the particle surface is obtained by: 
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where λi is the polymer-solvent relaxation time at the particle surface. 
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The drug transport in the polymeric network (iii) is modeled according to the following equation: 

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where D is the drug diffusion coefficient in the polymer matrix. Equation 5.2.17 represents the 
drug mass balance relative to the ith class of particles, i.e. the class of particles of radius Rpi. The 
first right-hand side term of eq 5.2.17 describes the drug transport due to the existence of a 
concentration gradient and a convective field (vi) induced by the stress gradient caused by the 
solvent absorption from the release environment. Indeed, by assuming that the stress gradient acts 
similarly to a pressure gradient in a pipe, the non-fickian solvent flux may be regarded as the cause 
of a convective field defined by: 
pii
i
i
vvi CvR
DJ =
∂
σ∂
−=
                                                                                                           (5.2.18) 
Equation 5.2.17 implies the existence of the dissolved and undissolved drug in the swelling 
polymeric network. While the undissolved drug is unable to move, the dissolved drug mobility is 
controlled by its diffusion coefficient, which depends on the local solvent concentration according 
to Peppas-Reinhart’s theory (Peppas and Reinhart, 1983): 





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−=ϕ= ϕ−
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−
s
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ds ρ
1          e i
i C
D
D h
                                                                                          (5.2.19) 
In eq 5.2.19, Dds represents the drug diffusion coefficient in the pure solvent, h is a model 
parameter to be determined, while φi is the local polymer volume fraction. Indeed, in polymeric 
matrices, depending on the adopted drug loading technique, the drug may be found in the 
amorphous, nanocrystalline, and microcrystalline states (Grassi et al., 2006). As nanocrystals and 
the amorphous drug are characterized by a higher solubility than microcrystals (Coceani et al., 
2012), their presence is able to have a significant effect on drug bioavailability. Whatever the state 
is, the drug dissolution rate is assumed to be proportional (being Kam, Knc, and Kmc the 
proportionality constants for the amorphous, nanocrystalline, and microcrystalline drugs, 
respectively) to the difference between Ci and the drug solubility ( amsC , ncsC , and mcsC , 
respectively, for the amorphous, nanocrystalline, and microcrystalline drugs): 
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As the amorphous drug is often unstable and, when dissolving, generally transforms itself into the 
more thermodynamically stable microcrystalline condition (iv), its solubility reduces with time 
according to Nogami’s theory (Nogami et al., 1969): 
( ) mcsrmcsams0ams e CCCC tK +−= −                                                                                                (5.2.23) 
where Kr is the recrystallization constant and ams0C  is the amorphous drug solubility. Obviously, 
the drug recrystallization may also occur in the release environment: 
( )mcscrrbrcd
d CCKV
t
M
−=
                                                                                                      (5.2.24) 
where Mc, Krb, and mcscC  are, in the release environment, the amount of recrystallized drug up to 
time t, recrystallization constant, and microcrystalline drug solubility, respectively. 
The solution of eq 5.2.17 is performed by assuming that, initially in the particles, no dissolved 
drug exists (it is possible to find only the solid or amorphous drug in the polymeric network) and 
the solid and/or amorphous drug concentrations are uniform. Finally, for symmetry reasons, the 
drug flux in the particle center is set to zero and the usual drug partition condition at the particle-
solvent interface is considered. In order to face the issue of the balance between the number of 
problem unknowns (CGICS, CL, CP, CT, Cpi, Ci, Cr) and that of equations, it is necessary to write a 
further equation for the definition of Cr. In particular, the drug overall mass balance is adopted: 
( ) ( ) ( ) ( )[ ]
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++++++
+++++= ∑ ∫
=
                                   (5.2.25) 
where M0 is the administered drug dose, Npi is the number of particles belonging to the ith class 
(Npi may be evaluated by eq 5.2.1). Equation 5.2.25 states that, anytime, the drug amount in the 
release environment, particles (the sum of integrals), GICS, liver, plasma, and tissues plus Mc and 
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Mel must be equal to M0. Interestingly, the use of eq 5.2.25 is allowed only if the other kinetic 
equations (5.1.5
 
–
 
5.1.9) are expressions of the drug mass balance in the different body 
compartments (GICS, liver, plasma, and tissues). 
Due to the simultaneous presence of ordinary and partial differential equations, the solution of the 
model required a numerical algorithm running on computers as a FORTRAN program. In 
particular, the ordinary differential equations were converted into linear algebraic equations 
according to the implicit Euler’s method (Chapra and Canale, 1998), while the implicit control 
volumes strategy (Patankar, 1986) (20 particles classes, 20 radial subdivisions) was considered for 
the partial differential equations conversion into linear and non-linear algebraic equations. In order 
to ensure the numerical solution accuracy, the integration time step was set to 1 s. Gauss-Seidel’s 
approach was employed for the iterative solution of the algebraic equations system, while the 
relaxation method was utilized to accelerate the solution convergence (Chapra and Canale, 1998). 
 
5.3. Results 
One of the critical factors connected with the use of PBPK models is the availability of reliable 
values for model parameters. Naturally, this is an important issue (Poulin et al., 2011a; Jones et 
al., 2011; Ring et al., 2011; Vuppugalla et al., 2011; Poulin et al., 2011b) because different values 
for the same parameter may be found in the literature, in some cases, due to the considerable 
variability of the subjects involved in tests (Podczeck, 2010; Newton, 2010; Yuen, 2010; Wilson, 
2010; Varum et al., 2010; Bowles et al., 2010; Pinto, 2010). Accordingly, in order to simplify the 
comparison of the three drugs considered in this study (theophylline, temazepam, and nimesulide), 
it was decided to rely exclusively on only one source (Di Muria et al., 2010) for parameters values. 
The first active principle, theophylline (THE), also known as 1,3-dimethylxanthine, is a 
methylxanthine drug with a wide clinical use in the treatment of respiratory diseases such as 
asthma. Its physicochemical and PK characteristics are displayed in Table 5.3.1. Figure 5.3.1 
shows the results of the model simulations for an orally administered THE dose of 100 mg 
dispersed in a 1 cm3 polymeric carrier. In particular, the continuous thick solid line refers to the 
THE concentration in the plasma in the case of a spherical matrix of 6200 µm radius. The initial 
part of the curve, characterized by zero drug concentration, is related to the drug residence in the 
stomach, where permeability was set to zero. Then, CP slowly increases to a maximum and remains 
steady. The CP increasing trend corresponds to the drug absorption in SIL and LIL, a result of the 
simultaneous action of the drug release from the matrix and the following absorption, distribution, 
metabolism, and elimination (ADME) phenomena. The main reason for low CP values is the very 
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slow trend 
Table 5.3.1. Model parameters for microcrystalline theophylline. 
PK parameters (Di Muria et al., 2010) 
VP(ml) VL(ml) VGICS(ml) VT(ml) 
11000 1500 9.96 24000 
QPV(ml/s) QHA(ml/s) QHV(ml/s) CLH(ml/s) 
16.25 5.41 21.6 0.4333 
re
elk (s–1) kel(s
–1) kTP(s–1) kTP(s–1) 
0.0 2.8
 
.
 
10-6 10-6 10-6 
tGL(s) RGL(cm) i
GLR (cm) PGL(cm/s) 
2880 7.5 0.0 0.0 
tSIL(s) RSIL(cm) i
SILR (cm) PSIL(cm/s) 
11520 2.5 0.0 7.0
 
.
 
10-4 
tLIL(s) RLIL(cm) i
LILR (cm) PLIL(cm/s) 
115200 2.5 0.0 3.5
 
.
 
10-4 
Delivery parameters (Grassi et al., 2000) 
Cpe(g/ml) e
fD (cm2/s) Dds(cm
2/s) mc
sC (g/ml) 
0.31 10-7 8.2
 
.
 
10-6 12.495 
ρd(g/ml) Kmc(s–1) Kr(s–1) Krb(s–1) 
1.47 1.0 0.0 0.0 
λe1(s) λe2(s) λe3(s) λe4(s) 
4.7
 
.
 
10-2 4.7
 
.
 
10-1 4.7 47 
E0(Pa)  E1(Pa) E2(Pa) E3(Pa) 
32972 85438 54674 43378 
E4(Pa) rf(nm) Vr(ml) Kp(-) 
76791 1.0 250 1 
 
slow drug delivery kinetics (the low ratio between the release surface and the matrix volume, 
typical of large spheres) from the matrix as depicted in Figure 5.3.2 (see the continuous thick solid 
line). By keeping constant the delivery system volume (1 cm3), its splitting into equal smaller 
particles leads to a much faster CP increase. In particular, the thin solid line and the dashed line of 
Figure 5.3.1 represent, respectively, the CP trend referred to particles characterized by a radius 
equal to 620 µm (about 103 particles) and 62 µm (about 106 particles). It may be observed that the 
drug concentration rise is fast and, after 2.5 h, CP reaches about 5 µg/ml in the first case (620 µm) 
and about 6.5 µg/ml in the second one (62 µm). Further reductions of particles size leaves the CP 
trend unaffected. Indeed, as Figure 5.3.2 demonstrates, when the particles radius is around 62 µm, 
the drug totally and very rapidly dissolves in the release environment (the stomach fluids), thus 
reaching the maximum value compatible with the administered dose, i.e. 400 µg/ml. In this case, 
no control over the drug release is exerted and the delivery system ensures a prompt and total 
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concentration 
  
Figure 5.3.1. Theophylline plasma concentration (CP) for different spherical delivery systems of 
the same volume (1 cm3) and dose (100 mg). The number near each curve indicates the diameter 
of the considered sphere(s), while the gray line refers to a polydispersed ensemble of spherical 
particles whose diameter ranges from 0 to 1240 µm. In the 6200 µm case, the numerical solution 
subdivides the particle into 500 control volumes, while the 620 µm ones into 200 and those of 62 
µm into 20. In the polydispersed case, the particles distribution was subdivided into 20 classes, 
while the generic particle of each class in 20 control volumes. 
 
release in the stomach. In other words, no difference is observed in the CP trend induced by this 
formulation or a drug solution of the same dose. Moreover, the CP trend shown by the 62 µm 
particles may be approximately obtained by the ensemble of polydispersed particles described by 
eq 5.2.1 with the following parameters: η = 700 µm, δ = 2, Rmin = 0 µm, and Rmax = 1200 µm (see 
the gray line in Figure 5.3.1). The difference, when using a polydispersed distribution, is a lower 
drug concentration (see the gray line in Figure 5.3.2) in the stomach fluids, which is advantageous 
in the case of stomach wall aggressive drugs. Finally, it is worthwhile underlining that, depending 
on the PK parameters displayed in Table 5.3.1, the time evolutions of CGICS and CL are 
substantially equal to the CP one. The rationale are the small CIGS (VGICS = 10 ml) and liver (VL = 
1500 ml) volumes in comparison to the plasma (VP = 11000 ml) and tissues (VT = 24000 ml) ones, 
including the relatively high volumetric flow among the various compartments (QHV, QPV, and 
QHA; see Figure 5.1 and Table 5.3.1). On the contrary, CT, in the scarcely perfused tissues and 
organs (“tissues” in Figure 5.1), monotonically increases, thus reaching, for all formulations, 
values which are about two orders of magnitude smaller than CP (see Figure 5.3.3). This is 
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essentially due to the higher value of the tissues volume (VT = 24000 ml). Interestingly, for the 
smaller particles, CP falls into the THE therapeutic window corresponding to 5 – 15 µg/ml. 
 
Figure 5.3.2. Theophylline concentration in the release environment (Cr) for different spherical 
delivery systems of the same volume (1 cm3) and dose (100 mg). The number near each curve 
indicates the diameter of the considered sphere(s), while the gray line refers to a polydispersed 
ensemble of spherical particles whose diameter ranges from 0 to 1240 µm. In the 6200 µm case, 
the numerical solution subdivides the particle into 500 control volumes, while the 620 µm ones 
into 200 and those of 62 µm into 20. In the polydispersed case, the particles distribution was 
subdivided into 20 classes, while the generic particle of each class in 20 control volumes. 
 
The second drug, temazepam (TEM), a benzodiazepine derivative characterized by sedative and 
hypnotic actions, was selected being possible to load it into a polymeric carrier (such as cross-
linked polyvinylpyrrolidone particles) in a completely amorphous form (Grassi et al., 2000). 
Indeed, this aspect is highly advantageous as amorphous TEM is characterized by a much higher 
solubility (around 8649 µg/ml) with respect to the microcrystalline drug solubility (about 164 
µg/ml). In absence of certain values for TEM PK parameters, those of a similar drug (Di Muria et 
al., 2010) were adopted, while all other model parameters were set according to a previous study 
(Grassi et al., 2000) (see Table 5.3.2). The concentration trends were simulated by considering an 
ensemble of polydispersed particles described by eq 5.2.1 with the following parameters: η = 5.96 
µm, δ = 3.88, Rmin = 0.3 µm, and Rmax = 7 µm. Figure 5.3.4 clarifies that amorphous TEM (gray 
line) produces, in PK terms, a better performance with respect to crystalline TEM (black line). 
Indeed, amorphous TEM not only yields a slightly higher CP maximum but also the CP peak occurs 
more than 10 minutes before the one of its crystalline form. This simulation was performed by 
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effect  
 
Figure 5.3.3. Theophylline concentration in tissues (CT) for different spherical delivery systems 
of the same volume (1 cm3) and dose (100 mg). The number near each curve indicates the diameter 
of the considered sphere(s), while the gray line refers to a polydispersed ensemble of spherical 
particles whose diameter ranges from 0 to 1240 µm. In the 6200 µm case, the numerical solution 
subdivides the particle into 500 control volumes, while the 620 µm ones into 200 and those of 62 
µm into 20. In the polydispersed case, the particles distribution was subdivided into 20 classes, 
while the generic particle of each class in 20 control volumes. 
 
assuming that no amorphous TEM recrystallization occurs in the stomach, although there is 
evidence of the contrary in water (Grassi et al., 2000). Indeed, as the recrystallization kinetics may 
strongly depend on the physicochemical properties of the dissolving fluids (the stomach fluids 
significantly differ from water), the lack of certain information about the TEM recrystallization in 
the stomach fluids pushes to neglect recrystallization this time. By doing this, the maximum 
possible effect of amorphous TEM in respect of crystalline TEM was estimated. Figure 5.3.5 
shows that, in the amorphous case, Cr rapidly reaches the maximum value (224 µg/ml) compatible 
with the administered dose (100 mg). This phenomenon, obviously, occurs in GL (t < 0.8 h), while, 
once in SIL and eventually LIL, Cr decreases to zero. In the crystalline case, on the contrary, the 
Cr increase is smaller and the maximum value is well below that reached in the amorphous case. 
At the same time, the Cr reduction in SIL and LIL is slower, thus ensuring higher CP from 
approximately 2 hours onward. Finally, CT, in the scarcely perfused tissues and organs (“tissues” 
in Figure 5.1), monotonically increases, thus reaching, for all formulations, values which are of 
the same order of magnitude of CP (see Figure 5.3.6). This is essentially due to the higher tissues 
0 4 8 12 16 20 24
C T
(µ
g/
m
l)
t(h)
0 - 1240 µm
620 µm
62 µm
6200 µm
0.1
0.08
0.06
0.04
0.02
5-16 
 
volume (VT = 152000 ml). 
 
Figure 5.3.4. Amorphous (gray line) and crystalline (black line) temazepam concentrations in the 
plasma (CP) for a polydispersed ensemble of spherical particles with a diameter ranging from 0.3 
to 7 µm, a global volume of 1 cm3, and a drug dose of 100 mg. The particles distribution was 
subdivided into 20 classes, while the generic particle of each class in 20 control volumes. 
 
 
Figure 5.3.5. Amorphous (gray line) and crystalline (black line) temazepam concentrations in the 
release environment (Cr) for a polydispersed ensemble of spherical particles with a diameter 
ranging from 0.3 to 7 µm, a global volume of 1 cm3, and a drug dose of 100 mg. The particles 
distribution was subdivided into 20 classes, while the generic particle of each class in 20 control 
volumes. 
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Table 5.3.2. Model parameters for temazepam. 
PK parameters (Di Muria et al., 2010) 
VP(ml) VL(ml) VGICS(ml) VT(ml) 
229000 1500 9.96 152000 
QPV(ml/s) QHA(ml/s) QHV(ml/s) CLH(ml/s) 
16.25 5.41 21.6 16.46 
re
elk (s–1) kel(s
–1) kTP(s–1) kTP(s–1) 
0.0 0.0 6.4
 
.
 
10-5 10-6 
tGL(s) RGL(cm) i
GLR (cm) PGL(cm/s) 
2880 7.5 0.0 0.0 
tSIL(s) RSIL(cm) i
SILR (cm) PSIL(cm/s) 
11520 2.5 0.0 6.0
 
.
 
10-4 
tLIL(s) RLIL(cm) i
LILR (cm) PLIL(cm/s) 
115200 2.5 0.0 3.0
 
.
 
10-4 
Delivery parameters (Grassi et al., 2000) 
Cpe(g/ml) e
fD (cm2/s) Dds(cm
2/s) ρd(g/ml) 
0.31 10-7 7.2
 
.
 
10-6 1.35 
mc
sC (g/ml) ncsC (g/ml) amsC (g/ml) K
mc(s–1) 
0.164 0.224 8.649 0.1 
Knc(s–1) Kam(s–1) Kr(s–1) Krb(s–1) 
0.1 0.1 0.007 0.0 
λe1(s) λe2(s) λe3(s) λe4(s) 
4.7
 
.
 
10-2 4.7
 
.
 
10-1 4.7 47 
E0(Pa)  E1(Pa) E2(Pa) E3(Pa) 
32972 85438 54674 43378 
E4(Pa) rf(nm) Vr(ml) Kp(-) 
76791 1.0 250 1 
 
The last drug is nimesulide (NIM), a typical non-steroidal anti-inflammatory largely employed in 
the clinical practice (Bernareggi, 1998). Similarly to TEM, it is scarcely soluble in aqueous media, 
but its solubility is pH-dependent as it is a weak acid (pKa = 6.46) (Fallavena and Schapoval, 
1997). Obviously, NIM solubility may be improved by using its amorphous/nanocrystalline form 
(Coceani et al., 2012). In addition, the first-pass effect for NIM is negligible (Bernareggi, 1998). 
While some PK parameters (Di Muria et al., 2010; Grassi et al., 2006; Bernareggi, 1998) and all 
delivery parameters (Grassi et al., 2000; Coceani et al., 2012) may be gathered from the literature, 
no reliable estimation of the NIM solubility in the gastric environment and of the permeability 
through GL, SIL, and LIL mucosae were available. Therefore, the model was fitted (four fitting 
parameters) to the experimental data referring to the oral administration (three humans) of a 
commercial prompt action NIM formulation (100 mg). The fitting procedure was performed by 
assuming that NIM in microcrystalline form is loaded into a polymeric carrier showing the 
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(Grassiet al., 2006  
 
Figure 5.3.6. Amorphous or crystalline temazepam concentration in tissues (CT) for a 
polydispersed ensemble of spherical particles with a diameter ranging from 0.3 to 7 µm, a global 
volume of 1 cm3, and a drug dose of 100 mg. The particles distribution was subdivided into 20 
classes, while the generic particle of each class in 20 control volumes. 
 
physicochemical characteristics displayed in Table 5.3.3, which are similar to those of the 
polyvinylpyrrolidone particles considered in the TEM case. Furthermore, iGLR  was set to 7.3 cm 
in such a way that the stomach absorption surface equals the one normally present in humans 
(around 1 m2) (Grassi et al., 2006). Figure 5.3.7 shows the agreement between the model best 
fitting (black line) and the experimental data (open circles) after assuming, as fitting parameters, 
mc
sC  = 39 µg/ml, PGL = 4.9 . 10–4 cm/s, PSIL = 1.1 . 10–4 cm/s, and PLIL = 6 . 10–5 cm/s. These 
permeability values indicate that NIM is rapidly absorbed by the gastric mucosa, while its 
absorption in SIL and LIL is slower. These results appear reasonable. Indeed, the acid environment 
of the stomach is particularly favorable for the absorption of NIM because, at lower pH than 3, 
this drug is completely undissociated. On the contrary, for higher pH such as the SIL one, NIM is 
partially or totally dissociated, thus preventing the drug from crossing the lipophilic mucous 
membrane. Accordingly, its physicochemical properties should be responsible for the NIM 
different permeability through the GI tract rather than the effect of intestinal wall transporters or 
other phenomena. These physicochemical considerations are supported by studies regarding the 
local absorption of NIM (Bernareggi and Rainsford, 2005; PPL 322, 1999) conducted on healthy 
volunteers (gamma scintigraphy). Indeed, these tests proved that the stomach and the proximal 
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small bowel account for 40% of the NIM absorption. As in the TEM case, the NIM absorption 
may be improved by employing its amorphous form. Figure 5.3.7 depicts CP (gray line) in the case 
of amorphous NIM by assuming, as for TEM, that no recrystallization occurs (Krb = 0). Hence, 
amorphous 
Table 5.3.3. Model parameters for nimesulide. 
PK parameters (Di Muria et al., 2010; Jain et al., 1981; 
Grassi et al., 2006; Bowles et al., 2010; Bernareggi, 1998) 
VP(ml) VL(ml) VGICS(ml) VT(ml) 
5000 1500 9.96 13000 
QPV(ml/s) QHA(ml/s) QHV(ml/s) CLH(ml/s) 
16.25 5.41 21.6 0.49 
re
elk (s–1) kel(s
–1) kTP(s–1) kTP(s–1) 
0.0 0.0 10-6 10-6 
tGL(s) RGL(cm) i
GLR (cm) PGL(cm/s) 
2880 7.5 7.3 4.9
 
.
 
10-4 
tSIL(s) RSIL(cm) i
SILR (cm) PSIL(cm/s) 
11520 2.5 0.0 1.1
 
.
 
10-4 
tLIL(s) RLIL(cm) i
LILR (cm) PLIL(cm/s) 
115200 2.5 0.0 0.6
 
.
 
10-4 
Delivery parameters (Grassi et al., 2000; 
Camera-Roda and Sarti, 1990; Coceani et al., 2012) 
Cpe(g/ml) e
fD (cm2/s) Dds(cm
2/s) ρd(g/ml) 
0.31 10-7 10-6 1.49 
mc
sC (g/ml) ncsC (g/ml) amsC (g/ml) K
mc(s–1) 
0.039 (pH < 6.4) 
0.1 (pH > 6.4) 
0.058 (pH < 6.4) 
0.15 (pH > 6.4) 
4.108 2.0 
Knc(s–1) Kam(s–1) Kr(s–1) Krb(s–1) 
2.0 2.0 0.06 0.0 
λe1(s) λe2(s) λe3(s) λe4(s) 
4.7
 
.
 
10-2 4.7
 
.
 
10-1 4.7 47 
E0(Pa)  E1(Pa) E2(Pa) E3(Pa) 
32972 85438 54674 43378 
E4(Pa) rf(nm) Vr(ml) Kp(-) 
76791 1.0 250 1 
 
this prediction should represent the maximum expected effect of amorphous NIM. It is noticeable 
that the maximum concentration is considerably increased and, up to about 5 hours, the drug 
concentration is higher than that of the crystalline case. This behavior in the plasma is explained 
by Figure 5.3.8, where Cr is shown for the amorphous (gray line) and crystalline (black line) drug. 
In the amorphous case, NIM is rapidly released in the first 3 minutes and its concentration is higher 
than that corresponding to the crystalline case. This means that its onset of action is considerably 
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onset  
 
Figure 5.3.7. Amorphous (gray line) and crystalline (black line) nimesulide plasma concentration 
(CP) for a polydispersed ensemble of spherical particles with a diameter ranging from 1 to 10 µm, 
a global volume of 1 cm3, and a dose of 100 mg. The open circles indicate the experimental data 
(the average of three subjects) which the model was fitted to (black line). The particles distribution 
was subdivided into 20 classes, while the generic particle of each class in 20 control volumes. 
 
Figure 5.3.8. Amorphous (gray line) and crystalline (black line) nimesulide concentration in the 
release environment (Cr) for a polydispersed ensemble of spherical particles with a diameter 
ranging from 1 to 10 µm, a global volume of 1 cm3, and a dose of 100 mg. The particles distribution 
was subdivided into 20 classes, while the generic particle of each class in 20 control volumes. 
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Figure 5.3.9. Amorphous (gray line) and crystalline (black line) nimesulide concentration in 
tissues (CT) for a polydispersed ensemble of spherical particles with a diameter ranging from 1 to 
10 µm, a global volume of 1 cm3, and a dose of 100 mg. The particles distribution was subdivided 
into 20 classes, while the generic particle of each class in 20 control volumes. 
 
increased, a desirable feature for a rapid pain relief. Moreover, in this case, the time evolutions of 
CGICS and CL are substantially equal to the CP one for the same rationale observed in the case of 
THE. Again, CT in the scarcely perfused tissues and organs monotonically increases, thus reaching, 
for all formulations, values that are about two orders of magnitude smaller than CP. The abrupt 
increase of Cr occurring after 1 h, in both the crystalline and amorphous cases, is due to the reduced 
value of PLIL. Indeed, that reduction implies the decrease of the drug flux leaving the release 
environment which, in turn, causes a drug concentration increase. 
 
5.4. Conclusions 
While the problem of a reliable evaluation of the drug concentration in the plasma subsequent to 
the oral administration remains challenging, a major step toward its solution is represented by 
mathematical models able to simultaneously take account of the in vivo drug release and the 
succeeding ADME processes. With this end in view, a sound mathematical model, resulting from 
merging a physiologically oriented PK model and a delivery one, was developed. Aiming to obtain 
reliable in vivo simulations, at present, the useful tool developed in this study is able to compare 
different formulations of the same drug or the same formulation of different drugs. Indeed, this 
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theoretical approach allows evaluating the effect of different doses, various particles mean sizes 
or distributions, and different solid forms, i.e. amorphous, nanocrystalline, and microcrystalline. 
It also demonstrates that the in vivo release kinetics may behave differently from the in vitro one 
owing to the effect of living tissues. In other words, while the mutual dependence of the drug 
release and the ADME processes is known, this work represents an attempt to carefully quantify 
that interplay. In conclusion, the presented model appears to be a rational basis for designing state-
of-the-art delivery systems and may constitute an important step toward dependable simulations 
of the plasma drug concentration subsequent to the oral administration. Finally, it is important to 
underline that the PK part of the model may be easily improved by adding further compartments 
or relations among compartments (Chiarappa et al., 2017). For instance, the periodic enteropathic 
circulation of bile – produced by the hepatocytes, stored in the gallbladder, and delivered to the 
duodenum by means of Oddi’s sphincter, which opens/closes depending on the digestive processes 
– may be considered if necessary. The reason for this “simplicity” resides in the fact that all these 
additional features, mathematically speaking, are represented by ordinary differential equations 
whose integration in the proposed model is straightforward. Indeed, in the light of the implicit 
Euler’s method employed for their resolution, those equations represent nothing but further linear 
equations. 
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CHAPTER 6 
 
CONCLUSIONS AND PERSPECTIVES 
 
 
The thermodynamic model built in the present thesis allows evaluating the effect of size and shape 
on the melting temperature (Tm) and enthalpy (∆Hm) of organic (drug) nanocrystals. In particular, 
the differences existing among spherical, cylindrical, and parallelepiped-shaped nanocrystals, 
characterized by different shape ratios (from needles to platelets), are explained in terms of the 
ratio between the number of the surface and bulk molecules. Indeed, the higher this ratio is, the 
higher the Tm and ∆Hm reductions are and, consequently, the higher the drug solubility is. As a 
solubility increase is reflected in a drug bioavailability enhancement, the considerable practical 
effect of nanocrystals geometry on nanocrystals based delivery systems clearly emerges. 
Model reliability, tested in the case of well-known poorly water-soluble drugs (nimesulide, 
griseofulvin, and nifedipine), is supported by the fact that the predicted solubility increase is 
physically sound in relation to the solubility of the amorphous drugs, which is expected to be 
considerably higher. In addition, model reliability was also proved by the results obtained from a 
molecular dynamics approach, which confirms the Tm and ∆Hm reduction predicted by the 
thermodynamic model and the effect of shape ratio variation. Accordingly, this model may be 
considered a reliable tool for the characterization/design of nanocrystals based delivery systems 
(the estimation of Xnc and nanocrystals size distribution in polymer-drug systems) and for the 
evaluation of nanocrystals solubility increase, an aspect of paramount importance for the 
bioavailability enhancement of poorly water-soluble drugs. Moreover, as it relies on 
thermodynamics, the developed model potentially holds for every drug and its polymorphic forms 
which may be significant in the pharmaceutical field. Clearly, it requires the knowledge of a certain 
number of fundamental physical parameters such as surface tension, density, Tm∞, and  ∆Hm∞ of 
the specific drug/polymorphic species. Furthermore, the presented model constitutes the starting 
point for the development of a thermodynamic model able to consider the actual shape of drug 
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nanocrystals (typically appearing in form of complex prisms) and the possible variation of surface 
energy on the various crystal facets. 
Nevertheless, in the present thesis, in order to evaluate the bioavailability enhancement deriving 
from the use of nanocrystalline and amorphous drugs, a physiologically oriented mathematical 
model aimed at studying in vivo drug release, absorption, distribution, metabolism, and 
elimination (ADME), with particular attention to the use of drugs embedded in polymeric matrices, 
was also developed. In fact, quite recently, the Pharmaceutical Research and Manufacturers of 
America tested the reliability of predictive models in terms of drug efficacy, safety, and properties 
estimation. In particular, physiologically based pharmacokinetic (PBPK) models, useful 
theoretical tools for the evaluation of the hepatic clearance and tissue distribution by resorting to 
in vitro and in silico data, showed, in the 69% of the cases, a medium-high degree of accuracy in 
simulating the time variation of the plasma drug concentration in humans following the 
intravenous administration, while, on the contrary, accuracy appeared to decrease to 23% in the 
case of oral administration. 
Predicting the time variation of the drug concentration in plasma/blood following the oral 
administration presents the considerable difficulty of simulating both the delivery and the 
absorption stages. In this light, being the oral administration the most common one, the present 
project attempted to establish a deep connection between ADME phenomena and the delivery of 
drugs in the form of macro and nanocrystals. In particular, the considered delivery system consists 
of an ensemble of non-eroding polydispersed polymeric particles loaded with the drug. Particulate 
systems, indeed, easily disperse within the stomach resulting in an appreciable decrease of local 
drug concentration and, as a consequence, a considerable reduction of the insurgence of gastric 
irritations. 
The adopted mathematical representation of the human body relies on the PBPK model developed 
by Di Muria and co-workers: the release environment fluids, due to peristalsis, flow from the 
gastric environment to the small and large intestine. Once the drug leaves the delivery system, it 
first reaches the gastrointestinal release environment fluids and then, by permeating the 
gastrointestinal mucous membranes, the gastrointestinal circulatory system (GICS). Afterward, 
through the portal vein, it enters the liver where it undergoes a partial elimination by metabolic 
clearance. Finally, the drug reaches the plasma through the hepatic vein. From the plasma, the drug 
may be exchanged with the less perfused tissues and return to the liver through the hepatic artery 
or to the GICS through the portal vein. 
The delivery model assumes that drug release kinetics is essentially determined by the polymeric 
particles size distribution in the dry state and their swelling on contact with the release environment 
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fluids, the drug dissolution and diffusion within the swollen particles, and the possible 
recrystallization of amorphous or nanocrystalline drugs in the release environment fluids. In 
particular, the swelling process, aside from the traditional fickian diffusion, considers a non-
fickian component of the solvent flux representing a delayed flux induced by the polymer-solvent 
couple viscoelastic character. The existence of two contributions in the solvent flux is motivated 
by the fact that polymeric chains undergo rearrangements which develop with time after the 
solvent uptake, i.e. the relaxation phenomena. Interestingly, this viscoelastic behavior of polymeric 
meshes also affects the drug release from the delivery system. Indeed, the convective field induced 
by the stress gradient due to the fluid uptake into the particles acts similarly to a pressure gradient 
inside a pipe. 
The constructed model was then tested against three widely used drugs: theophylline (no solubility 
issues), temazepam (low solubility), and nimesulide (low solubility). This mathematical model 
allows comparing different formulations of the same drug or the same formulation for different 
drugs, evaluating the effect of different doses, various particles mean sizes or distributions, and 
different solid forms, i.e. amorphous, nanocrystalline, and microcrystalline. One of the most 
noteworthy results of this study is the quantitative evaluation of the interplay between release 
kinetics and the subsequent ADME processes. Indeed, it is usually assumed that the in vivo drug 
release coincides with the in vitro one with the result of neglecting the effect of the ADME 
processes. In fact, the proposed model demonstrates that the in vivo release kinetics may be 
different from the in vitro one due to the effect of living tissues. In conclusion, the present model 
may be taken into consideration and further developed as a useful tool for the design of different 
oral delivery systems. 
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